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ABSTRACT 
 Approximately two-thirds of breast cancers result from overexpression of the estrogen 
receptor, a ligand-dependent transcription factor. Traditional therapy employs drugs that bind 
directly to the receptor but do not mediate transcription. Unfortunately most breast cancers 
develop resistance to these antagonists. The mechanism of this resistance is not fully known. 
This thesis describes two different approaches to circumventing this resistance. 
 In Chapter 2, the unique anti-proliferative and anti-inflammatory activity of a lead 
compound, OBHS, is described. A crystal structure of OBHS bound to the estrogen receptor 
provided the basis for structural and functional analogs of OBHS. These compounds exhibited 
weaker binding to the estrogen receptor than OBHS; however some displayed comparable anti-
inflammatory activity. 
 In Chapter 3, compounds were designed and synthesized in order to inhibit the binding of 
the estrogen receptor to coactivator proteins that facilitate transcription. We used a 
peptidomimetic approach to mimic conserved amino acids on the coactivator proteins. 
Compounds designed in this way did not inhibit the interaction between the estrogen receptor 
and a coactivator protein. 
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Chapter 1: The Role of the Estrogen Receptor in Breast Cancer and Implications for Therapy 
1.1 INTRODUCTION 
The American Cancer Society estimated approximately 192,000 new cases of invasive 
breast cancer and 40,000 deaths caused by breast cancer in 2009. Only skin cancer has a higher 
incidence, and only lung cancer has a higher mortality rate. Approximately two-thirds of breast 
cancers are estrogen receptor (ER) positive, meaning they have elevated levels of this protein.  
1.2 THE ESTROGEN RECEPTOR 
The ER belongs to the nuclear hormone receptor superfamily of ligand-dependent 
transcription factors. Other nuclear hormone receptors, which are closely related to the estrogen 
receptor in structure and function, include the androgen, progesterone, and glucocorticoid 
receptors. The ER controls a wide variety of biological functions, partly due to its widespread 
and diverse tissue distribution. Both female and male reproductive systems express the ER; 
inappropriate activity of ER in this tissue leads to disease states such as breast, uterine and 
ovarian cancer. Additionally the ER can be found in the cardiovascular, skeletal and central 
nervous systems. Estrogens have important effects on maintaining bone health and various 
cognitive functions. Several endocrine-disrupting compounds (EDCs) exert some of their 
developmental toxicity through estrogenic pathways in the brain. Thus, the ER provides a target 
for understanding the causes of cancer and developing novel treatments. 
1.3 MOLECULAR MECHANISM 
ER and other nuclear hormone receptors contain five domains (Figure 1.1): (1) the N-
terminal A/B domain containing an activation function-1 (AF-1) region; (2) the DNA binding 
domain (DBD), also called the C-domain; (3) the hinge region, also called the D-domain; (4) the 
E-domain, containing the ligand-binding domain (LBD) and an activation function-2 (AF-2) 
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region; and (5) the C-terminal F-domain. Both the AF-1 and the AF-2 mediate transcription; the 
AF-1 acts in a ligand-independent fashion, but the response is not as strong as that of the ligand-
dependent AF-2. The AF-1 domain also contains sites for post-translational modification via 
phosphorylation of certain amino acid residues.  
The ER exists as one of two subtypes, ERα and ERβ, which have different distributions 
among the various tissues and cell types.
1
 ERα is found in higher concentrations in the uterus, 
prostate stromal cells, Leydig cells of the testes, epididymis, bone and breast. ERβ is found in 
higher concentrations in the epithelium of the prostate, granulosa cells of the ovary, and bone 
marrow. Various regions of the brain also contain different relative levels of ERα and ERβ. The 
two ER subtypes have high sequence identity in the DBD (97%), some identity in the LBD 
(56%), and little identity in the A/B, D, and F domains. Both ERα and ERβ bind the 
endogeneous ligand for the ER, 17β-estradiol (E2), with high affinity; the affinity is slightly 
higher for ERα than ERβ. Although overall the ligand binding domains of ERα and ERβ have 
only modest sequence conservation, the ligand-binding pocket of ERβ is only different from ERα 
in two significant ways. First, the volume of the ERα binding pocket is approximately 490 Ǻ, 
whereas the volume for the ERβ pocket is approximately 390 Ǻ.2 The change in pocket volume 
reflects the mutation of Leu 384 to a methionine and Met 421 to an isoleucine. 
At the molecular level, the function of the estrogen receptor is dictated by its 
conformation, which in turn depends on the nature of the bound ligand. E2 is a largely planar, 
hydrophobic molecule with two hydrogen bond donors: a phenyl hydroxyl group on the A-ring, 
which forms a hydrogen bond network with Glu353 and Arg394, and an aliphatic hydroxyl 
group on the D-ring, which forms a hydrogen bond with His524. The A-ring phenol hydrogen 
contributes more to the energy of binding than the D-ring hydroxyl hydrogen. The formation of 
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these hydrogen bonds favors a conformation of the receptor in which the C-terminal helix (helix 
12) folds over the surface of the receptor and creates a hydrophobic groove on the surface, as 
shown in Figure 1.2. The coactivator proteins responsible for facilitating transcription contain 
conserved LXXLL motifs, which bind in this groove. At the ends of the grooves are two charged 
amino acids, K362 and E542, which form a charge clamp; this charge clamp forms hydrogen 
bonds with residues outside the LXXLL box. There are several classes of these coactivator 
proteins, including the p160 class and the p300 class. The p160 class contains the steroid 
receptor coactivator (SRC) proteins; the p300 class contains CBP and related proteins. These 
proteins were initially known for their ability to recruit transcription machinery. Later, it was 
discovered that some of these proteins possess histone aceyltransferase activity.
3
 Acetylation of 
lysines on the histone proteins, around which DNA is coiled, facilitates the uncoiling of DNA 
necessary for transcription. Figure 1.3 summarizes this process. Chapter 3 discusses attempts to 
inhibit the ER-coactivator interaction. 
1.4 TYPES OF LIGANDS AND THERAPY 
The ER binds an eclectic set of ligands, which can be steroidal or nonsteroidal, as well as 
synthetic or naturally occurring. (Figure 1.4) One of the earliest synthetic nonsteroidal estrogenic 
ligands was diethylstilbestrol (DES), which is a very potent agonist. DES was used in treatment 
for infertility and risk of premature delivery until it was observed that women who had been 
exposed to DES in utero developed a cancer rare form of vaginal cancer at an early age.
4
 
Reproductive and developmental toxicity has also been observed in males.
5
 Faslodex, on the 
other hand, is a potent steroidal full antagonist. Faslodex contains a long sulfoxide-containing 
aliphatic side chain which extends from the binding pocket towards the coactivator binding 
groove. This prevents helix 12 from adopting the agonist conformation and subsequent 
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coactivator protein binding. Naturally occurring estrogenic compounds include genistein found 
in high levels in soy, and its analaogs and metabolites. Various pesticides and herbicides have 
also been shown to have estrogenic activity, although the affinities of these compounds for the 
ER are often quite low. 
Clinically, breast cancer and other diseases in which the ER is implicated are treated by a 
class of compounds called selective estrogen receptor modulators (SERMs). These compounds 
have an aminoethyl side chain that functions in a manner similar to the long side chain found on 
Faslodex (Figure 1.2c). These compounds may function as antagonists or agonists, depending on 
cellular context. Two of the most commonly used SERMS, tamoxifen and raloxifene, are shown 
in Figure 1.5. Tamoxifen acts as an agonist in uterus and bone tissue, but as an antagonist in 
breast tissue. Raloxifene, on the other hand, acts as an agonist in bone tissue, but an antagonist in 
both uterus and breast. Due to its antagonist action in breast tissue, tamoxifen has been 
effectively used for the treatment of breast cancer. However, prolonged treatment with tamoxifen 
leads to recurrence of cancer.
6
 It appears that, over time, tamoxifen begins to act as an agonist. 
Mechanisms that might explain this phenomenon will be discussed later in this introduction. 
An alternative to SERM therapy is the class of compounds known as aromatase inhibitors 
(AIs). Two of these are shown in Figure 1.5. The biosynthesis of E2 concludes with oxidation of 
testosterone to E2, which generates the aromatic A ring of E2. The enzyme responsible for this 
process is a member of the cytochrome P450 family (CYP19A1), which is also known as 
aromatase. Inhibition of this enzyme starves ER-positive tumor cells of E2 needed for receptor 
function. Unfortunately, resistance is also seen with AIs; this may result from ligand-independent 
activation of ER, which will be described below. 
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1.5 THREE-DIMENSIONAL STRUCTURE OF POCKET 
 While the structure of estradiol is largely planar, it was predicted and later confirmed by 
x-ray crystallography that the binding pocket is significantly larger than estradiol. Unoccupied 
space exists above and below the plane of E2 (Figure 1.6); filling this space with hydrophobic 
groups might increase binding affinity. This partially explains the high binding affinity of DES; 
the ligand flips so that the ethyl chains extend vertically in the pocket (Figure 1.7). Many have 
tried to design ligands with inherent three-dimensional structures that would fill up the binding 
pocket and interact with the hydrophobic ceiling and floor of the binding pocket. Endo has 
designed bicyclooctanes
7
 and carboranes with phenol rings as three-dimensional estrogen 
ligands. The Katzenellenbogen group has synthesized cyclopentadienyl rhenium compounds 
with carbonyl ligands, giving the core a three dimensional structure as models for PET-imaging 
agents.
8
 The group has also synthesized oxabicyclic compounds with moderate binding 
affinities.
9
 One of these compounds displayed unusual and promising anti-inflammatory activity 
in addition to its antagonistic activity. Design of analogs based on this compound will be 
discussed in Chapter 2. 
1.6 ER AND INFLAMMATION 
The exact mechanism of tamoxifen resistance remains unclear, but it may be related to 
the ability of SERMS to act as agonists, when their structure indicates they should function as 
antagonists. This agonistic activity may proceed through extranuclear estrogenic pathways. In 
the cytoplasm, the ER interacts with complex signal transduction cascades. One example of these 
is the MAPK pathway, which is involved in cell growth and cell death. The MAPK pathway 
begins with various growth factors binding to receptors on the cell surface. These receptors 
phosphorylate kinases, which phosphorylate downstream kinases. Ultimately, transcription 
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factors are activated by phosphorylation, and gene expression is activated. Some of these kinases 
phosphorylate the ER, which leads to gene expression modulated by the ER in a ligand-
dependent manner.
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Another pathway involves cross-talk between the ER and NF-κB, a family of 
transcription factors activated in response to stress signals. Inflammatory triggers such as 
endotoxins (e.g., lipopolysaccharide), tumor necrosis factor α (TNFα), growth factors and 
reactive oxygen species bind to cell surface receptors in a manner analogous to the MAPK 
pathway. These transmembrane receptors initiate a similar phosphorylation cascade (Figure 1.8). 
NF-κB is sequestered in the cytoplasm by IκB proteins, which block the nuclear localization 
sequence of NF-κB. An upstream kinase, IκK phosphorylates IκB, rendering it susceptible to 
post-translational modification by addition of a small protein called ubiquitin to lysine residues 
on the protein. After several more ubiquitin proteins are added to additional sites, or to 
previously added ubiquitins, IκB becomes susceptible to degredation by the proteasome. This 
process releases NF-κB, which is then free to enter the nucleus and exert its activation of 
transcription. The estrogen receptor is known to inhibit NF-κB, although the mechanism is not 
fully understood. As both the ER and NF-κB are transcription factors found in the nucleus and 
cytoplasm, there are many possible levels of interaction.  
Several studies have investigated the interaction between NF-κB and the ER. In spinal 
cord astrocytes, addition of ER inhibited expression of the CCL2 cytokine, the expression of 
which is controlled by NF-κB.11 Interestingly, ER did not prevent the translocation of NF-κB to 
the nucleus, indicating that the cross-talk may involve interactions at the DNA-binding level. 
ChIP assays showed that ER inhibits binding of NF-κB to the CCL2 gene promoter. CCL2 
expression levels decreased after treatment an ERα selective agonist. 
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  Nettles et al. explored ability of the ER to mediate the expression of monocyte 
chemoattractant  protein-1 (MCP-1), which is activated by NF-κB.12 MCP-1 expression was 
inhibited in MCF-7 cells using E2 and other ER agonists, but not by hydroxytamoxifen. Pull-
down assays showed that removal of the LBD, but not any other domain, inhibited the ability of 
the ER to inhibit NF-κB activity. The coactivator protein CBP proved to be an essential 
component of the ER–NF-κB interaction. E2 caused the ER to displace CBP from NF-κB. 
 The crosstalk between the ER and NF-κB has provided a new target for breast cancer 
therapy, particularly those with underlying inflammation. Wyeth Pharmaceuticals developed 
several classes of ligands as anti-inflammatory compounds that would act in an ER-dependent 
manner (Figure 1.9). The first series of compounds, 3-arylindazoles, showed nanomolar 
inhibition in an NF-κB reporter gene assay in cells also transfected with ER.13 These compounds 
showed little or no uterine weight increase in vivo, and weak creatine kinase stimulation. One of 
these compounds, WAY-169916, has been investigated in further studies. In a high-throughput 
screen, an additional scaffold containing a hydroxyphenylsulfonamide was discovered.
14
 
Derivatives of a lead compound showed comparable activity to WAY-169916. Finally, 
cyanopropionates were shown to have good NF-κB activity with low ER activity designed for 
the treatment of rheumatoid arthritis.
15
 In collaboration with Kendall Nettles at The Scripps 
Research Institute in Jupiter, Florida, we have identified a lead compound with low ER binding 
activity but strong inhibition of estrogen-dependent inflammation pathways; this compound, and 
efforts to design similar compounds, will be discussed in Chapter 2.  
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1.7 FIGURES 
 
Figure 1.1 The functional domains of the ER mapped  to its sequence. 
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(A) (B)  
(C)  
Figure 1.2 (A) ER in the agonist conformation, with bound E2 (space-filling model). Shown in green is helix 12, which folds 
over E2 to create the coactivator binding groove (triangle). A fragment of an NR Box from a coactivator protein is shown in gold. 
(B) Electrostatic potential map of the coactivator binding groove. Areas with partial positive charge are colored red, areas with a 
partial negative charge are colored blue, and nonpolar areas are colored teal. The ILXXLL fragment of a coactivator peptide is 
shown as a red tube, with only the conserved leucine / isoleucine residues shown. (C) ER in the antagonist conformation, bound 
to TOT. The basic side chain protrudes towards the area occupied by helix 12 in the agonist conformation. Helix 12, which now 
blocks the coactivator binding groove, is shown in red. 
  
10 
 
 
Figure 1.3 Schematic of the mechanism of action by which ER activates expression of target genes. 
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Figure 1.4 Structures of endogeneous estrogens, synthetic agonists, phytoestrogens and xenoestrogens. 
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Figure 1.5 Structures of SERMs, antagonists and aromatase inhibitors. 
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Figure 1.6  Representation of the binding pocket of ER. Key hydrogen bonds are made between ARG394 and GLU353 and the 
3-hydroxyl group, as well as HIS524 and the 17-hydroxy group. The total volume of the binding pocket is represented by green 
dots. A representation of the molecular surface of E2 is shown in yellow. 
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Figure 1.7 The binding pocket of ER in the presence of DES. Green dots represent the receptor pocket volume. The electrostatic 
potential map of DES is colored yellow. The two ethyl groups extend into space not occupied by E2. 
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Figure 1.8 The NF-κB pathway. Signaling molecules are shown outside the cell, which initiate phosphorylation of proteins in the 
cytoplasm. Ultimately p50, p52, and members of the Rel family (which heterodimerize to form NF-κB units) are freed from IκBα 
and enter the nucleus to activate various genes.16 
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Figure 1.9 Inhibitors of NF-κB developed by Wyeth for treatment of inflammation. 
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Chapter 2: Design, Synthesis, and Evaluation of OBHS and Analogs 
2.1 INTRODUCTION 
Design behind initial oxabicyclic compounds 
The search for synthetic estrogens and anti-estrogens has mostly focused on designing 
estrogens with planar structures, mimicking the near planarity of E2.  Various heterocyclic cores 
have been synthesized with aryl and aliphatic substituents. Cores having similar arrangements of 
phenols and alkyl chains can have markedly different activities, despite overlaying very well 
with each other.
1
 As mentioned in Chapter 1, three dimensional ligands have been synthesized in 
order to fill the binding pocket more completely. With this in mind, the Katzenellenbogen group 
and others have designed ligands with a more three-dimensional structure. The diarylethylene 
motif found in tamoxifen was incorporated into cyclohexane
2
, bicyclononane
3
 and adamantane 
cores.  The latter two ligands possess extraordinary binding affinities compared to E2. We 
developed a 7-oxabicyclo[2.2.1]heptene scaffold to create three-dimensional ligands with good 
affinity.
4
 Several compounds in this series were synthesized and tested for ER binding activity in 
our radiometric binding assay. In these assays the binding affinities are expressed as a percentage 
of the binding affinity of E2, or relative binding affinity (RBA). This value is calculated as Ka 
(E2) / Ka (ligand). Most of these ligands exhibited weak affinities; the RBAs of the best 
compounds ranged from 1% to 10%. 
These ligands were included in a library of compounds given to Kendall Nettles of The 
Scripps Research Institute at Jupiter, Florida, who was searching for new anti-inflammatory 
compounds; these compounds were also submitted to high-throughput crystal structure 
experiments. The Y537S ER mutant,
5
 which is constitutively active, was used in these crystal 
studies. This mutation stabilizes folding of helix 12 into the active conformation, creating a 
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binding pocket similar to that seen in agonist structures. Use of this mutant increases the 
likelihood that the ER will crystallize with a ligand bound even if the ligand is only a weak 
agonist. Nettles was able to obtain crystal structures of the ER with low-affinity ligands in a 
combinatorial fashion. Two of the crystal structures obtained by this method contained ligands 
from the oxabicyclic series with very low binding affinities.
6
 These crystal structures showed 
unusual distortions in the crystal structure, which will be described in more detail later. The 
Katzenellenbogen and Nettles groups are collaborating to determine whether these observations 
in the crystal structure lead to any novel biological activities. 
The ER inhibits the NF-κB mediated inflammatory response, although the mechanism by 
which this inhibition occurs is unclear. Considering both ER and NF-κB are present in the 
cytoplasm and the nucleus, their interaction may occur in either location. They may bind 
directly, they may communicate via a bridging factor, they may compete for common 
coactivators, or they may influence shared signal transduction pathway. 
Preliminary Biological Results from the Nettles Lab 
Fortunately one of the oxabicycloheptene ligands showed promising results in anti-
inflammatory assays. This compound also happened to be the oxabicyclic ligand with the highest 
ER activity. This ligand, termed OBHS (oxabicycloheptenesulfonate), was subjected to 
additional inflammatory assays in the Nettles group, which are described below. In these assays 
OBHS is compared to tamoxifen, which is not expected to inhibit the NF-κB pathway. In fact, 
the tamoxifen resistance mentioned in Chapter 1 may result from activation of this pathway by 
tamoxifen. 
In preliminary studies from the Nettles lab OBHS showed promising activity in reporter 
gene assays using MCF-7 cells measuring either ER or NF-κB activity. ER transcription assays 
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showed that OBHS acted as an antagonist in a manner similar to tamoxifen. In NF-κB 
transcription assays, tamoxifen was unable to inhibit gene expression; both OBHS and E2 were 
able to inhibit NF-κB – mediated gene expression. Taken together, these results suggested that 
OBHS had the potential to address a dilemma in traditional endocrine cancer therapy. ER-
positive cancer cells proliferate in the presence of agonists; the agonists allow the ER to inhibit 
the inflammatory response associated with a poorer prognosis in breast cancer. Traditional 
therapy that antagonizes the ER (such as SERMs) suppresses the anti-inflammatory activity of 
the ER. OBHS showed a biological profile reminiscent of the Wyeth compounds developed for 
the treatment of arthritis and other inflammation. OBHS has a better ER binding affinity than the 
Wyeth compounds; the significance of the ER binding affinity depends on the role of ER in 
inhibiting NF-κB. 
 Additional experiments were conducted in the Nettles lab to determine if ER is required 
for the unique activity of OBHS. In reporter gene assays conducted in ER-negative cells OBHS 
was unable to inhibit activation of pro-inflammatory genes. If ER was cotransfected into the 
same cells, OBHS regained its anti-inflammatory activity. Additionally anti-inflammatory assays 
were conducted in the presence of the pure ICI 182,780 antagonist in addition to OBHS or 
dexamethasone, a non-estrogenic inhibitor of NF-kB – mediated inflammation. ICI was able to 
block the activity of OBHS but not dexamethasone. These results taken together strongly suggest 
a role for ER in the activity of OBHS. 
To further test the role of macrophages in stimulation of breast cancer cell growth, MCF-
7 cells and macrophages were grown by the Nettles group in wells separated by a semi-
permeable membrane. Thus, the cells did not contact each other directly, but communicated 
through cytokines and other signaling factors. The presence of macrophages caused increased 
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proliferation in the MCF-7 cells; this effect was increased by the addition of tumor necrosis 
factor α (TNF-α), a known initiator of the NF-κB pathway.  In the absence of macrophages 
tamoxifen was able to inhibit proliferation. In the presence of macrophages and TNF-α, 
tamoxifen was unable to inhibit proliferation. Only OBHS was able to inhibit proliferation with 
or without the addition of macrophages, and was able to do so in a dose-dependent fashion. 
Tamoxifen was able to inhibit IL-6 mRNA production, as long as macrophages were not present. 
Even in the absence of macrophages, tamoxifen was unable to inhibit CCL5 mRNA production. 
OBHS, on the other hand, was able to inhibit IL-6 and CCL5 gene transcription, even in the 
presence of macrophages. 
Analysis of proteins known to be regulated by NF-κB also showed that OBHS inhibits 
NF-κB mediated transcription. The mRNA levels for two proteins involved in inflammation and 
cell growth were measured. Both IL-6 and CCL5 were induced by TNFα in MCF-7 cells with or 
without the addition of macrophages. In addition to measuring cancer cell proliferation, the 
growth of macrophages was also examined. The same activity seen in MCF-7 cells was also seen 
in macrophages, indicating that OBHS inhibits both cancer and macrophage proliferation. 
Inspired by these results we synthesized several grams of OBHS for use in animal 
studies. Professor Nettles and colleagues prepared a mouse model for breast cancer by injection 
of MCF-7 cells. The growth of these cells was inhibited by either tamoxifen or OBHS; the 
tamoxifen-induced inhibition of tumor growth is not surprising. We were pleasantly surprised to 
find that OBHS also decreased tumor progression (Figure 2.1).  When macrophages were also 
injected into mice with MCF-7 cells, the tumors began to grow at a much faster rate, and under 
these conditions, tamoxifen was unable to prevent or decrease tumor growth. Only OBHS was 
able to cease tumor progression in some cases; in most cases OBHS treatment caused complete 
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tumor loss (Figure 2.2). Analysis of NF-κB activity and levels of IL-6 and CCL5 in treated 
animals confirmed the results seen from in vitro tamoxifen or OBHS treatment (Figure 2.3). We 
do not know of any other compounds which show such promising activity in a model of breast 
cancer exacerbated by inflammation. Therefore, we set out to design structural and functional 
analogs of OBHS as potential breast cancer therapeutic agents, and to further understand the 
unique and promising mechanism of action. 
2.2 DESIGN AND SYNTHESIS 
2.2.1 Crystal structure analysis 
 Professor Nettles obtained crystal structures of three oxabicyclic compounds: OBHS, and 
two diester derivatives with very low RBAs. The crystal structures of the low-binding esters 
showed some significant distortions from the E2 crystal structures. These effects were magnified 
in the OBHS structure. One of the main effects seen in the crystal structures is a deviation in 
helix 11, the start of which forms the dimer interface and the end of which can interact with helix 
12 in certain circumstances. Helix 11 is the longest helix in the ER structure, although the length 
of this helix varies between structures of different ligands. In the crystal structure of OBHS, the 
helix begins to unwind at an earlier point than in other crystal structures. The loop between helix 
11 and helix 12 is also greatly distorted in the crystal structure (Figure 2.4), although loops tend 
to be disordered in crystal structures. Additionally, His 524, which normally participates in 
hydrogen bonding with the 17-OH group of E2, is flipped out so that it is unable to participate in 
hydrogen bonding (Figure 2.5). The unusual distortions in the crystal structure of OBHS can be 
quantified by measuring the deviation at each residue between the E2 crystal structure and the 
OBHS crystal structure (Figure 2.6). The structures are almost identical through the middle of 
helix 11, except for some regions in the structure that correspond to unresolved residues in one 
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of the structures. The only significant difference in the crystal structure is seen in residues 
following His 524; the largest deviation is seen from residues 528 to 531. Computational studies 
indicate that His 524 also participates in a hydrogen bonding network which includes amino 
acids from several helices.
7
 Thus, it is possible that OBHS disrupts the dimer interface and 
creates a coactivator binding groove different from that formed by other ligands. Since the 
crystal structure was obtained using a mutant that favors the agonist conformation, it may not 
provide an accurate representation of the coactivator binding groove in the presence of OBHS.  
We used the crystal structure as a basis for design of structural and functional analogs of 
OBHS. We first made additional compounds containing the oxabicyclic core as structural 
analogs. We were also interested in creating a general design for ligands which would exhibit the 
unusual NF-κB activity of OBHS. These compounds would not necessarily contain the 
oxabicyclic scaffold, but would contain functional groups that are necessary to induce a 
conformation of the ER induced by OBHS; necessary components would include the 1,2-
diarylethylene moiety and a bulky pendant aryl group that would occupy the same space in the 
crystal structure as the phenyl sulfonate. 
2.2.1 OBHS analogs containing a single phenol hydroxyl group 
The first set of analogs synthesized were designed to investigate the role of the phenols, 
as one of the crystal structures of a low-affinity bicyclic analog indicated that only one of these 
phenols participated in a hydrogen bond. The original synthesis was used, with some 
modifications, to synthesize analogs of OBHS containing only one phenol (Scheme 2.1). A 
phenacyl bromide was alkylated with 4-methoxyphenylacetic acid with Et3N as the base in 
acetonitrile to generate ester 1. The phenacyl ester was treated with crushed KOH in acetonitrile 
to produce the diarylbutenolide 2. This butenolide could be reduced with DIBAL-H, but 
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deprotection of the resulting furan under acidic conditions caused decomposition due to the acid 
sensitivity of furan. Thus the butenolide was deprotected in neat pyridine hydrochloride at 220 
°C, yielding 3 without need for further purification. 
While these first three reactions could be carried out in high yields with minimal 
purification on a multi-gram scale, the selective DIBAL reduction proved to be more difficult, 
especially on a multi-gram scale. On smaller scales, adequate yields of the furan could be 
obtained after acidic workup. Unfortunately the yields could not be reproduced when using more 
than 10 mmol of 3. Several attempts were made to develop a synthesis that would be easily 
scalable, and allow for introduction of diversity on the two aryl groups. These attempts will be 
described later. Ultimately the problem was solved by switching to an inverse quench of the 
DIBAL into methanol. When methanol is added to large quantities of DIBAL and the 
intermediate hemiacetal, both will be quenched. If the aluminum adduct is hydrolyzed while 
DIBAL is still present, the hydroxyenal will be reduced to a butenediol, reducing the yield. By 
inverse quenching into a large excess of MeOH, the excess DIBAL and the aluminum adduct 
will be quenched quickly. Usage of this inverse quench procedure increased the yield of furan 4 
to as high as 75%. 
The final step in the synthesis of oxabicyclic ligands was the Diels-Alder reaction with 
diarylfurans and various dienophiles. In our group’s previous study, sulfonate and sulfone 
dienophiles were the most successful; accordingly we focused on these same dienophiles while 
exploring substitution patterns on the phenyl rings. The furan and diene were heated neat at 90 – 
100 °C for 6 to 18 hours. The 
1
H NMR spectra were consistent with an exo adduct, using NMR 
analysis described by Zhou et al.
4
 Analogs 5 containing only one phenol hydroxyl group were 
obtained as a mixture of regiosiomers, ranging from 1:1 to 4:1 after purification. 
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 The oxabicyclics above were synthesized as racemates. Asymmetric Diels-Alder 
reactions are not known for the reaction between furans and vinyl sulfonates. Furan itself has 
been used in asymmetric auxiliary-based and catalyzed Diels-Alder reactions;
8, 9
 these reactions 
typically give endo products under kinetic control, with a few exceptions. Before attempting to 
synthesize enantiopure OBHS, we wanted to know if there was a significant difference in 
binding affinities between the two enantiomers. Analytical chiral HPLC showed the two isomers 
could be readily separated using an (R,R)-Whelk OS-1 column. An (S,S)-Whelk OS-1 column 
was used for semi-preparative separation of the enantiomers. Approximately one milligram of 
each enantiomer was obtained. The HPLC traces for the racemate and each enantiomer are 
shown in Figure 2.7. 
2.2.2 Attempted improvements on OBHS synthesis 
 Before improvements were made to the large scale synthesis of OBHS, an improved 
method was sought. An ideal synthesis would be more amenable to scale-up, and avoid low-
yielding reactions at the end of the synthesis. Additionally, we were interested in modifying the 
two phenol-containing rings while avoiding the production of inseparable regioisomers. Towards 
this end, several routes to OBHS were investigated. 
Zhou et al.
4
 prepared 3,4-diarylfuranby carbometalation of 3-phenyl-propynol with 
phenylmagnesium bromide, according to a general procedure developed by Fallis.
10
 This method 
generated highly substituted furans, albeit with low yields in many cases. However, this 
procedure did not work when changing the Grignard reagent to 4-methoxyphenylmagnesium 
bromide. The reaction appears to fail at the carbometalation step, as no consumption of propargyl 
alcohol was observed (Scheme 2.2) 
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3,4-Diarylfurans have also been synthesized by coupling of a 3,4-bisstannylfuran with 
aryl halides, or with 3,4-dihalofurans with aryl nucleophiles.
11, 12
 The 3,4-bisstannylfuran has 
been synthesized from a Diels-Alder / retro Diels-Alder sequence with 
bis(trialkylstannyl)acetylene and phenyloxazole.
13
 This reaction was carried out at very high 
temperature in the literature, but did not produce the product in high yield, and thus was not 
attempted (Scheme 2.3). Baldwin described a synthesis of 3,4-dibromofuran from trans-2,3-
dibromo-2-buten-1,4-diol using aqueous potassium dichromate. Unfortunately this procedure 
could not be reproduced (Scheme 2.4). The same product can be obtained by bis-stannylation of 
2-butyn-1,4-diol catalyzed by Pd to yield the cis-distannyl alkene, followed by oxidation to the 
furan.  Attempts at purification of the product of this reaction resulted in partial destannylation, 
giving a product that could not be separated from the distannane. cis-2,3-Diaryl-2-buten-1,4-
diols have been synthesized by a multi-component reaction using 1,4-dihydroxy-2-butyne, an 
aryl halide and an aryl boronic acid in the presence of palladium.
14, 15
 The arylpalladium 
intermediate produced from oxidative insertion into an aryl halide reacts with an alkyne to 
generate a vinylpalladium intermediate, which would then undergo a Suzuki coupling with the 
boronic acid. When carried out with 1,4-dihydroxy-2-butyne, 4-bromoanisole and 4-
methoxyphenylboronic acid, only the unproductive side-product resulting from a Suzuki reaction 
between the aryl bromide and aryl boronic acid was isolated. Using the same alkyne with 4-
methoxyphenylboronic acid under an atmosphere of oxygen (as a stoichiometric palladium 
oxidant), the same biphenyl byproduct was observed. 
2.2.3 Bicyclic OBHS analogs 
 We turned to the synthesis of OBHS analogs in which the bridging oxygen would be 
replaced with a methylene or ethylene unit. We predicted that this change would lead to analogs 
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with higher ER binding affinity. The bridging oxygen in OBHS bound in the ER points either up 
or down towards a hydrophobic area of the binding pocket. Replacing the oxygen with carbon 
would provide a better match between ligand and receptor hydrophobicities. We attempted 
synthesis of both bicycloheptene and bicyclooctene; each has synthetic advantages and 
disadvantages. 
Bicyclo[2.2.1]heptene 
 The bicyclo[2.2.1]heptene adduct could be synthesized from a Diels-Alder reaction 
between a vinyl sulfonate and a 3,4-diarylcyclopentadiene. The desired cyclopentadiene has been 
synthesized by the Katzenellenbogen group as a precursor of a cyclopentadienyl ligand used in 
PET imaging.
16
 Cyclopentadiene itself is a very reactive diene in Diels-Alder reactions. 
However, substituted cyclopentadienes are less useful in Diels-Alder reactions, due to the 
presence of multiple regioisomers produced by rapid, reversible [1,5]-hydrogen shifts.  In some 
cases mono- and di-substituted cyclopentadienes undergo regioselective Diels-Alder reactions 
catalyzed by Lewis acids.
17-19
 In order to obtain the exo product, we hoped that the same thermal 
conditions used to make OBHS might be used with cyclopentadienes. At elevated temperatures, 
the [1,5]-hydrogen shift occurs rapidly.  The 2,3-diarylproduct was expected to react faster than 
either the 1,2-diarylcyclopentadiene or the 1,5-diarylcyclopentadiene, forming the desired adduct 
(Scheme 2.5).  
The route described previously was briefly explored using an expensive cyclopentenone 
as the starting material. Two other more economical routes to the desired cyclopentadiene were 
explored. In the first route (Scheme 2.6) cyclopentenone was treated with iodine in pyridine / 
ether to generate alpha-iodoeneone 6.  This iodoenone underwent a Suzuki reaction with 4-
methoxyphenylboronic acid using PdCl2(PhCN)2 as the catalyst, triphenylarsine as the ligand, 
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and silver oxide as the base to yield 7. Addition of 4-methoxyphenyllithium (generated in situ), 
followed by dehydration produced the cyclopentadiene 8, albeit in low yield as a 2:1 mixture of 
isomers. A higher-yielding route was developed (Scheme 2.7), starting with a condensation 
between p-anisil and acetone to generate 9.
20
 The hydroxycyclopentenone was reduced to 
cyclopentenone 10 with either refluxing HI/AcOH, or TMSCl/NaI as a milder alternative. 
DIBAL reduction of the cyclopentenone, followed by dehydration, produced cyclopentadiene 8. 
Curiously the NMR of this compound indicated a ca. 20:1 ratio of 1,2-diarylcyclopentadiene to 
2,3-diarylcyclopentadiene. Figure 2.8 shows the differences in the NMR spectra of 8 generated 
by the two routes described above. The product from DIBAL reduction was used in Diels-Alder 
reactions, as it was available in much larger quantities; 8 was subjected to Diels-Alder reaction 
conditions (with or without toluene as a solvent at temperatures ranging from 90 °C to 140 °C). 
Analysis of the crude product by HPLC, as well as attempts to purify the product by MPLC, 
indicated a complex mixture of at least 6 products (Figure 2.9).  Deprotection of isolated peaks 
which showed NMR signals consistent with desired Diels-Alder adducts yielded <1 mg of 
product; as a result, satisfactory characterization of a pure compound could not be obtained. 
Bicyclo[2.2.2]octenes 
We then explored synthesis of diarylcyclohexadiene precursors to bicyclo[2.2.2]octenes. 
Cyclohexadienes do not undergo [1,5]-hydrogen shifts, leading to only one regioisomer when 
using a symmetrical diene. The drawback to using cyclohexadienes in the Diels-Alder reaction is 
that the distance between the termini of the diene is significantly larger than that of aliphatic 
dienes or cyclopentadienes and furans. With appropriate Lewis acid catalysts, or elevated 
temperatures cyclohexadienes will undergo Diels-Alder reactions. Unlike the cyclopentadiene 
system described above, the desired 2,3-diarylcyclohexadienes are not known in the literature.  
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 Our attempts at cyclohexadienes began with alpha iodination of cyclohexenone to yield 
11 in a manner analogous to cyclopentenone (Scheme 2.8). Enone 12 was produced by Suzuki 
coupling with 4-methoxyphenylboronic acid using the PdCl2(PhCN)2 / Ph3As / Ag2O system 
previously described for cyclopentenone 6. At this point there are no known ways to add the 
second aryl group with the appropriate double bond position. Addition of 4-
methoxyphenylmagnesium bromide yielded a complex mixture of unknown products. Repeating 
the reaction with cerium chloride gave the cyclohexenol, but attempts to dehydrate the 
cyclohexenol regioselectively to the cyclohexadiene were unsuccessful. To install the second 
aryl group before the Diels-Alder reaction, we converted the cyclohexenone to the corresponding 
vinyl triflate 13 by generating the kinetic cross-conjugate enolate and quenching with Comins’ 
triflating reagent.
21
 This product could be obtained as a crude product in high yields. Attempts to 
further purify the product reduced the yield to 60%. The purified product only had limited 
stability when stored neat at -20 °C, so the crude product was usually used for attempted 
coupling reactions.  
Cyclohexadienyl triflates have undergone coupling reactions with Grignard reagents in 
the presence of copper catalysts, or with preformed organocuprates.
22
 The substrates used in this 
methodology did not contain bulky substituents adjacent to the triflate. Attempts to repeat this 
methodology using triflate 13 were unsuccessful (Scheme 2.9). Application of Suzuki reaction 
conditions found to be effective for installation of an aromatic group ortho to an existing 
aromatic group were tried. The reaction did not yield the desired product; in fact, the new 
product still contained the triflate. Low-resolution mass spectrometry indicated a loss of H2 
resulting in 15; oxidation had seemingly occurred even though the reaction was conducted under 
argon.  
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Unless the oxidation occurred from adventitious oxygen, some other mechanism must 
account for the aromatization. One possibility invokes the ability of boronic acids to abstract a 
hydride, forming a borohydride intermediate and cyclohexadienyl cation. Under the basic 
conditions typically employed in Suzuki reactions, β-elimination could generate the benzene 
product. If this were true, then using a nucleophile without an empty p orbital might prove to be 
a better coupling partner. Kumada couplings with aryl Grignard reagents using palladium, iron, 
or nickel catalysts did not generate the desired product, producing only starting material. We also 
investigated the slow-release MIDA boronate developed by Burke,
23
 as this technology only 
generates low concentrations of boronic acid. Efficient transmetalation would prevent the 
boronic acid from acting as an oxidant. The slow-release conditions, however, did not generate 
product, nor did use of Molander’s potassium trifluoroborate. Unable to install the second aryl 
group prior to the Diels-Alder reaction, we considered carrying out the Diels-Alder reaction on a 
cyclohexadienyl ether. Generating of the kinetic enolate as described above, but quenching with 
TBSCl or TBSOTf yielded TBS ether 14. Heating this diene with phenylvinyl sulfonate did not 
yield a Diels-Alder adduct; only oxidized starting material 16 was obtained (Scheme 2.9). 
We then moved from cyclohexadienes to acyclic butadienes to simplify the design. 
Acyclic dienes can exist in an s-trans conformation which is unreactive Diels-Alder reactions. 
2,3-diphenylbutadiene, however, is known to react in a Diels-Alder reaction.
24
 The crystal 
structure of this compound shows a nearly s-cis conformation, which would be reactive in the 
Diels-Alder reaction.
25
 A dihedral drive calculation provides computational support for the 
stability of the s-cis conformation. We attempted a double Wittig reaction of p-anisil to prepare 
the diaryldiene in one step; only one ketone reacted, resulting in enone 17 (Scheme 2.10). 4,4’-
Dimethoxybenzil reacted with methylmagnesium bromide to yield a mixture of dl- and meso 18. 
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Attempts to dehydrate the diol to form the diene resulted in 19 due to in a pinacol-type 
rearrangement. 
2.2.4 Functional Analogs of OBHS 
 Unable to generate carbocyclic OBHS analogs, we sought to develop an “outside-in” 
approach to designing new analogs containing the structural motifs in OBHS found to give 
optimum binding: a 1,2-diarylethylene framework with a pendant aryl group at an appropriate 
distance from the diarylethylene unit. 
Attempted chemical modifications of OBHS 
 The simplest approach was to replace the oxabicyclic core with a single ring. 
Dehydrating the core of OBHS proved to be more difficult than anticipated.  Both acidic (HCl, 
TFA, POCl3 and H2SO4) and basic conditions (KOtBu and LDA) were tried, but only starting 
material was observed. Treating OBHS with TMSI resulted in reduction of the oxabicyclic core, 
yielding a mixture of cyclohexenols. We then sought to synthesize dehydrated OBHS directly. 
1,2-Bis(4-methoxyphenyl)benzene was readily prepared by a double Suzuki reaction between 
1,2-dibromobenzene and 4-methoxyphenylboronic acid. Treatment of this compound with 
chlorosulfonic acid generated a sulfonic acid, which could not be converted to the sulfonyl 
chloride. 
Thiophene carboxamides 
 We then sought to replace the trisubstituted benzene with a trisubstituted heterocyclic 
core. We chose thiophene as a bioisostere of benzene. The synthesis began with a Suzuki 
coupling between 3-bromothiophene and 4-methoxyphenylboronic acid to generate thiophene 21 
(Scheme 2.11). This thiophene was regioselectively brominated at the 2 position with NBS. 2-
Bromothiophene 21 underwent a second Suzuki reaction to generate 2,3-diarylthiophene 22.  
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Lithiation of this thiophene, followed by quenching with CO2 provided the thiophene carboxylic 
acid 23. This carboxylic acid was coupled to primary aryl amines by either peptide coupling 
conditions or coupling to an in situ generated acid chloride. The resulting carboxamides 24 were 
deprotected to give the final products 25.  
Pyrazolo[1,5-a]pyrimidines 
We explored the use of pyrazolo[1,5-a]pyrimidines as scaffolds for OBHS functional 
analogs. This core has been used in ER ligands in the Katzenellenbogen group,
26, 27
 with 
maximum RBA values around 1%. This is not necessarily a deterrent to making analogs of these 
compounds, as the relationship between ER affinity and NF-κB antagonism is not clear. In fact, 
modest NF-kB antagonism was shown with the highest binding pyrazolopyrimidine, containing 
trifluoromethyl groups at the C5 and C7 positions.
28
  We wondered whether replacing one of the 
trifluoromethyl groups with a pendant aromatic group would increase the NF-κB antagonism. 
The synthesis began as previously reported (Scheme 2.12), with condensation between 4-
methoxyphenylacetonitrile and methyl 4-methoxybenzoate to yield α-cyanoketone 26. This 
intermediate was converted to aminopyrazole 27 by condensation with hydrazine. Condensation 
with 1,3-dicarbonyl compounds would generate the pyrazolo[1,5-a]pyrimidine. In the previous 
report, only symmetrical 1,3-diketones and aldehydes were used, so regiochemistry was not an 
issue. However, the new desired target compounds needed substitution at either the 5 or the 7 
position of the heterocyclic core. A follow-up report to our original study on 
pyrazolopyrimidines suggested a binding orientation, which we could use to determine where to 
position the pendant aromatic groups. Two sets of compounds were made in which one of the 
phenol hydroxyl groups was selectively alkylated with the basic dialkylaminoethyl side chain 
found in many SERMs. The phenol hydroxyl group on the aryl group at C2 was determined to be 
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more important than the one on the aryl group at C3, indicating that it acts as a mimic of the 3-
hydroxyl group of estradiol. Overlaying OBHS with the highest binding pyrazolopyrimidine 
indicated that the 5-CF3 group overlaps with the phenylsulfonate group. 
With this knowledge, we sought to synthesize a pyrazolopyrimidine with a synthetic 
handle for further functionalization at the 5- position. Regioselective syntheses of either 5- or 7- 
pyrazolopyrimidinones have been accomplished by choice of base and dicarbonyl electrophile. 
In one report, a condensation between aminopyrazoles and ethyl ethoxyacrylate in DMF, using 
cesium carbonate as the base, yielded the pyrazolopyrimidin-5-one.
29
 The authors used NMR 
data (chemical shift, coupling constant and NOE data) to determine the regioisomers. 
Presumably, under these conditions the heterocyclic nitrogen adjacent to the exocyclic amino 
group is the most reactive, and it undergoes a conjugate addition to the enoate, followed by 
elimination and cyclization to form the fused heterocyclic product. 
When these reaction conditions were repeated with the aminopyrazole to generate 28, the 
NMR data were consistent with the data reported for the pyrazolopyrimidin-5-one. This product 
was dehydrated to chloropyrazolopyrimidine 29 with POCl3 in refluxing toluene. Pendant 
aromatic groups were added by nucleophilic substitution with phenols in DMF, using potassium 
carbonate as the base. Deprotection of 30 afforded the final pyrazolopyrimidines 31. 
Benzo[b]thiophenes 
We also explored the possibility of converting traditional high affinity ligands into 
antagonists possessing the unique in vitro and in vivo profile of OBHS. The antagonism would 
come not from a basic side chain, as seen in SERMs, but from an appropriately positioned 
pendant aryl group mimicking the phenylsulfonate of OBHS. Others in the Katzenellenbogen 
group have converted tamoxifen, E2 and raloxifene into nontraditional antagonists. The binding 
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affinity of the tamoxifen derivatives remained high. The binding affinity of the E2 derivatives 
dropped roughly 10 fold, while the raloxifene derivatives bound very poorly. Further analysis of 
the raloxifene analogs docked into the ER binding pocket showed that flipping the location of the 
phenols and the pendant aryl group horizontally across the pocket might better position the sulfur 
near a very hydrophobic region of the pocket. 
The initial synthetic strategy was modeled after the known syntheses of the 
benzo[b]thiophene core of raloxifene, which use an intramolecular Friedel-Crafts acylation. In 
this case the aryl thiol used needed to have a para subsitutent which could be transformed into 
the pendant aryl group. Desoxyanisoin was brominated with Br2, generating 2-
bromodesoxyanisoin. This compound did not readily couple to 4-bromothiophenol. While 
attempting to improve this reaction, attempts were also made to determine whether the 
cyclization would proceed efficiently. 4-Bromothiophenol was coupled to α-bromo-4-
methoxyacetophenone. Cyclization with BF3 etherate or Eaton’s reagent failed to produce a 
benzo[b]thiophene. This cyclization is not described in the literature, perhaps due to the lack of 
electron density on the thiophenol ring. Thus, alternate syntheses of benzo[b]thiophenes with 
better literature precedent were explored. 
Larock has described the synthesis of fused heterocycles using an electrophilic 
iodocyclization of ortho substituted ethers, thioethers and amines to generate iodinated 
benzofurans, benzothiophenes or indoles. A large library of benzo[b]thiophenes were made by 
this route, including some very similar to our target compounds.
30
 This route was modified to 
allow for a handle at the 5-position of the benzo[b]thiophene core. A triflate was chosen, as it 
could be converted into a diarylamine, diarylether, or biaryl group via transition metal-catalyzed 
coupling reactions. To avoid the triflate reacting in coupling reactions in the synthesis, the 
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oxygen had to be masked with a protecting group that could be removed without removing 
methyl ethers protecting the required para substituted phenols. Initially the TBS group was 
investigated, but the isopropyl group was found to give better yields; TBS groups can 
occasionally be removed during silica gel chromatography, lowering yields. 
The synthesis began with alkylation of 3-iodophenol with isopropyl bromide in DMF, 
yielding 3-iodo-1-isopropoxybenzene 32 (Scheme 2.13). Compound 33 was produced by 
bromination with NBS in DMF overnight. Selective Sonogashira coupling with 4-ethynylanisole 
in triethylamine yielded 34. The bromide was converted to a thiomethylether by lithium-bromine 
exchange followed by quenching with dimethyl disulfide to generate 35. Addition of I2 in 
dichloromethane produced 3-iodobenzo[b]thiophene 36, which underwent a Suzuki coupling to 
yield diarylbenzo[b]thiophene 37. The isopropyl group was removed with AlCl3 in 
dichloromethane to furnish 5-hydroxybenzothiophene 38. 
Compound 38 could be directly coupled to aryl halides to generate biaryl ethers, which 
molecular modeling indicates would position the pendant aryl group in the same space that the 
phenyl group of the phenylsulfonate in OBHS occupies. Copper-catalyzed Buchwald-Hartwig 
etherification reactions were explored. Coupling to a few initial aryl iodides and halides using 
CuI and picolinic acid as the ligand did not generate the biaryl ether. We then decided to explore 
amination reactions. The triflate (39) and tosylate (40) of 38 were prepared and subjected to 
Buchwald-Hartwig amination conditions (Scheme 2.14). The tosylate was reacted with aryl 
amines using a highly active palladium catalyst generated by mixing Pd[(o-tol)3P]2 with a 
Josiphos ligand, CyPF. These conditions were reported to yield the product at room temperature; 
in our hands this was not the case. Even further heating to 80 °C did not effect product 
formation. Switching to the more reactive triflate, and using BINAP also did not produce the 
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desired diarylamine. Our group has had success using aryl bromides as the electrophile in these 
reactions. The Larock synthesis was modified to place a bromine at the 5 position. This new 
synthesis while using a more expensive starting material required fewer steps.  
4-Bromo-2-iodoaniline was converted to 4-bromo-2-iodothioanisole 41 by treatment with 
methyl disulfide and in situ diazotization with isoamyl nitrite (Scheme 2.15).
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 The same 
chemoselective Sonogashira conditions used previously were applied to the thioanisole, yielding 
42. Iodocyclization with I2 yielded 43. This benzo[b]thiophene underwent a Suzuki reaction 
selectively at the iodine to produce the 5-bromobenzo[b]thiophene 44, with varying amounts of 
5-arylated material also formed as byproducts. Addition of bromide 43, anilines, and NaOtBu to 
a solution of Pd(OAc)2 and BINAP, previously heated to 60 °C to effect dissolution, and heating 
to reflux in a sealed tube resulted in formation of the Buchwald-Hartwig biaryl products 45. 
Deprotection of the methyl ethers revealed the desired bisphenol compounds 46. 
2.3 ANALYSIS OF BIOLOGICAL ACTIVITY 
 The oxabicyclics containing only one phenol hydroxyl group bound to the ER with 
affinities approximately 20-fold lower than those of the analogous compound containing two 
phenol hydroxyl groups (Table 2.1). This is consistent with oxabicyclics containing one para 
phenol and either a para methyl ether or a meta phenol. These compounds had RBAs 
approximately 10-fold lower than the compounds containing two phenols. The crystal structures 
of several oxabicyclic compounds do not reveal a role for both phenols. However, the two 
phenols are oriented in the pocket in a similar fashion to the phenols in the high-affinity three-
dimensional agonists cyclofenil and bicyclononane. Two phenols are also required for high 
affinity in these compounds. Although it does not appear as a strong hydrogen bond acceptor, 
Thr347 has been implicated in interacting with the phenol extending into the binding pocket in a 
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direction originating from the 11β position of a bound steroid. From this point forward all of the 
compounds we made contained two phenols. 
 The two separated enantiomers of OBHS were determined to have RBAs of 3.24% and 
16.11% for ERα and 0.687% and 1.98% for ERβ. The average of these values agrees well with 
the observed value for the racemate. The absolute stereochemistry of the separated enantiomers 
has  not been determined. In the crystal structure of OBHS shown in Figures 4 and 5 the oxygen 
bridge is pointing downward in the pocket. It is likely, but not necessarily true, that the OBHS 
enantiomer in this structure is the higher binding enantiomer. Each enantiomer was docked into 
the OBHS crystal structure; the key structural components (i.e. the two phenols and the phenyl 
sulfonate) overlay very well with each other (Figure 2.10). In the crystal structures of two 
oxabicyclic analogs the oxygen bridge is pointing up in the box. From these data we proposed 
that planar compounds lacking the oxygen bridge would bind with reasonable affinity. 
 The binding affinities of the planar functional OBHS analogs are summarized in Table 
2.2. The pyrazolopyrimidine and thiophene ligands showed very low binding to the ER. This 
initially discouraged us from preparing additional analogs, as we had assumed ER affinity 
comparable to that of OBHS was necessary. OBHS had the highest binding affinity in its series, 
and was the only one to show the unusual NF-κB antagonism. The benzo[b]thiophenes exhibited 
the best RBAs of any of the planar functional analogs. These compounds are structurally 
analogous to the pyrazolopyrimidines; the only differences are the more nonpolar core, and the 
use of a nitrogen linkage instead of an oxygen linkage. The increase in RBA probably results 
from a more nonpolar core interacting more favorably with the nonpolar ER ligand binding 
pocket. Preliminary results from tamoxifen derivatives prepared by other Katzenellenbogen 
group members suggest that the NH- linkage affinity relative to the ether linker. 
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 Recently, our collaborators performed a screen of a set of about 100 compounds in 
transcriptional assays using liver cells, including some ligands designed as OBHS structural or 
functional antagonists. The data for OBHS and tamoxifen are shown in Figure 10. The dose-
reponse curves for E2 (solid line) and the indicated ligand (dashed lines) for ERα (red) and ERβ 
(blue). In this assay OBHS acts as an agonist with potency comparable to E2, but with 
diminished efficacy. When the assay was repeated in an antagonist mode, OBHS showed no 
antagonist activity on ERα, but good antagonist activity on ERβ. In our original studies using 
endometrial cancer cells, OBHS acted as an antagonist on both ERα and ERβ. In this screen 
pyrazolopyrimidine 31a showed poor ER activity, confirming what we had seen in our in vitro 
RBA assay, but also showed excellent inhibition of IL-6 expression. 
2.4 CONCLUSIONS 
 OBHS, a novel oxabicyclic ER ligand, represents an exciting therapeutic candidate for 
breast cancer. The potential of OBHS arises from its unique ability to act as an ER antagonist 
while still maintaining antagonistic activity towards NF-κB. OBHS has proven to be effective in 
vitro and in vivo. Encouraged by these results, we designed and synthesized structural and 
functional analogs of OBHS. These compounds have low affinity for the ER; most were also 
ineffective in NF-κB assays. One compound so far, 31a  has shown promising inhibition of NF-
κB mediated expression of IL-6. Our ability to generate novel ER / NF-κB antagonists will 
continue to lead to promising lead compounds in the treatment of breast cancer. 
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2.5 FIGURES 
 
Figure 2.1 In vivo administration of OBHS or tamoxifen in a xenograft mouse model of breast cancer. 
 
Figure 2.2 In vivo administration of OBHS or tamoxifen in a xenograft mouse model of breast cancer with injection of 
macrophages. The blue line refers to animals in which the tumor volume stayed constant (N =4); the red line refers to animals in 
which a decrease in tumor volume was seen (N = 14). 
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Figure 2.3 Analysis of levels of NF-kB activity, IL-6 and TNF-a levels in tissue samples. 
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Figure 2.4 The crystal structures of ERa bound to E2 (orange) or OBHS (teal). 
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Figure 2.5 The binding pocket of the ER bound to E2 (orange) and OBHS (teal). 
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Figure 2.6 RMSD between crystal structures of ER bound to three oxabicyclic ligands and E2. The spikes at residues 330 and 
460 result from gaps in the crystal structure of unresolved residues. The important deviations in the crystal structure occur from 
residue 527 to 531. 
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Figure 2.7 Chiral HPLC chromatogram of racemic OBHS (red trace), or reinjection of purified enantiomers (green and blue 
traces) separated on a Whelk OS-1 column using isopropanol:hexanes. 
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Figure 2.8 Comparison of 1H NMR spectra of 8 produced in Scheme 5 (top) and Scheme 6 (bottom; crude NMR shown). 
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Figure 2.9 MPLC chromatogram of Diels-Alder adduct between 8 and phenylvinyl sulfonate. 
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(A) 
 
 
 
 
(B) 
 
Figure 2.10 Enantiomers of OBHS docked into the OBHS crystal structure. 
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(A)  
(B)  
Figure 2.11 
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(C)  
(D)  
Figure 2.11 (cont.) 
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(E)  
(F)  
Figure 2.11 (cont.) 
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(G)  
(H)  
Figure 2.11 (cont.) (A), (C), (E), (G) Transcription assays in HepG2 cells for OBHS (A), tamoxifen (C), 31a (E) and 31b (G). 
(B), (D), (F), (H) Single point transcription assays for OBHS (B), tamoxifen (C), 31a (F)  and 31b. Assays were conducted with 
ERα containing only the LBD, full-length ERα or ERβ. ANT refers to assays conducted in the presence of E2. IL-6 data refer to 
mRNA levels of the IL-6 gene. 
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Scheme 2.1 Synthesis of OBHS and analogs. 
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Scheme 2.2 Carbometalation strategy of Fallis for synthesis of diarylfurans.10 
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Scheme 2.3 Diels-Alder approach to synthesis of diarylfurans. 
 
Scheme 2.4. Attempted syntheses of diarylfuran using double cross-coupling approaches. 
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Scheme 2.5 Expected distribution of products arising from Diels-Alder reaction of 8 with phenylvinyl sulfonate. 
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Scheme 2.6 Initial synthesis of diarylcyclopentadienes as precursors to OBHS analogs. 
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Scheme 2.7 Revised synthesis of diarylcyclopentadienes. 
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Scheme 2.8 Synthesis of cyclohexadienes. 
 
 
Scheme 2.9 Observed oxidation of cyclohexadienes under various reaction conditions. 
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Scheme 2.10 Attempted syntheses of 2,3-diarylbutadienes. 
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Scheme 2.11 Synthesis of thiophene carboxamides. 
 
61 
 
Scheme 2.12 Synthesis of pyrazolopyrimidines. 
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Scheme 2.13 First Larock synthesis of benzothiophenes. 
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Scheme 2.14 Attempted coupling of benzothiophene sulfonates. 
 
Scheme 2.15 Revised Larock synthesis of benzothiophenes. 
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Table 2.1 RBA data for oxabicyclic analogs. 
 
* RBA for ERα of analogs of 5b and 5c, except the phenyl group has been replaced by the 
indicated functional group. These data are taken from Zhou et al.
4
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Table 2.2 RBA data for planar, functional OBHS analogs. 
 
 
2.6 EXPERIMENTAL  
All reagents used were purchased from Aldrich Chemical Company, Fisher Scientific, or TCI 
America and used without further purification unless otherwise specified. Anhydrous THF, ether, 
dichloromethane, toluene, dioxane, DMF, DMSO, and acetonitrile were obtained from a solvent 
delivery system. Anhydrous triethylamine, diisopropylethylamine, and diisopropylamine were 
obtained by distillation from calcium hydride. When necessary, organolithium and 
organomagnesium reagents were titrated with menthol / 1,10-phenanthroline. Reaction progress 
was monitored by thin-layer chromatography (TLC) using glass-backed silica gel plates with 
fluorescent indicator. Unless otherwise specified, reaction temperatures refer to external bath 
temperatures. Flash chromatography was performed using 40-63 µm particle size (230 – 400 
mesh) silica gel from Silicycle. 
1
H and 
13
C NMR spectra were obtained on Varian 400 or 500 
MHz FT-NMR instruments. Chemical shifts (δ) are reported in parts per million and are 
referenced to residual undeuterated solvent peaks. Mass spectra were obtained on a Micromass 
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Quattro or Micromass Q-Tof mass spectrometer. Melting points were obtained on a Thomas-
Hoover apparatus and are uncorrected. 
General procedure A: Bromoacetophenone (1.0 eq) and 4’-methoxyphenylacetic acid (1.1 eq) 
were dissolved in acetonitrile (0.5M in bromoacetophenone). Triethylamine (1.1 eq) was added 
at once. The reaction stirred for 2 hours at room temperature. The acetonitrile was removed by 
rotary evaporation, and redissolved in ethyl acetate. The o rganic layer was washed with 1N HCl 
and brine, dried over MgSO4 and evaporated in vacuo, yielding a clear oil which solidified upon 
standing. This material was often of sufficient purity for the next reaction. If necessary, the 
product could be recrystallized from ethanol. 
2-(4-methoxyphenyl)-2-oxoethyl 2-(4-methoxyphenyl)acetate (1a) 
Following general procedure A, the product was obtained as white crystalline solid in 86% yield. 
1
H NMR (499 MHz, CDCl3)  7.81 - 7.93 (m, 2H), 7.20 - 7.35 (m, 2H), 6.92 - 7.00 (m, 2H), 6.83 
- 6.92 (m, 2H), 5.32 (s, 2H), 3.88 (s, 3H), 3.81 (s, 3H), 3.77 (s, 2H) 
13
C NMR (126 MHz, CDCl3)  190.8, 171.7, 164.2, 159.0, 130.7, 130.3, 127.4, 125.9, 114.3, 
114.2, 66.3, 55.8, 55.5, 40.3 
HR-MS (ESI): Calculated for C18H19O5 (M + H)
+
: 315.1232; found 315.1227 
2-oxo-2-phenethyl 2-(4-methoxyphenyl)acetate (1b) 
Following general procedure A, the product was obtained as a cream-colored powder in 92% 
yield and used without further purification. 
1
H NMR (400 MHz, CDCl3)  7.83 - 7.94 (m, 2H), 7.55 - 7.65 (m, 1H), 7.41 - 7.52 (m, 2H), 7.20 
- 7.32 (m, 2H), 6.82 - 6.95 (m, 2H), 5.35 (s, 2H), 3.80 (s, 3H), 3.77 (s, 2H) 
13
C NMR (126 MHz, CDCl3)  192.3, 171.6, 159.0, 134.4, 134.1, 130.7, 129.1, 128.0, 125.9, 
114.3, 66.6, 55.5, 40.2 
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LR-MS (EI): 284.1 
General procedure B: 
Phenacyl ester and 18-crown-6 (0.04 eq) were dissolved in acetonitrile (0.2M). With stirring, 
crushed KOH pellets (1.1 eq) were added. The reaction stirred for one hour, during which time 
the reaction color changed from clear to yellow to orange to dark green. The reaction was 
quenched with 3N HCl (1 mL HCl / 10-15 mL acetonitrile). The reaction turned yellow-orange; 
after a minute of stirring a yellow-orange solid precipitated. This solid was filtered and 
recrystallized from ethanol. 
3,4-bis(4-methoxyphenyl)furan-2(5H)-one (2a) 
Following general procedure B, the product was obtained in 97% yield. 
1
H NMR (500 MHz, CDCl3)  7.76 - 7.95 (m, 2H), 7.24 - 7.29 (m, 2H), 6.91 - 6.98 (m, 2H), 6.84 
- 6.90 (m, 2H), 5.31 (s, 2H), 3.87 (s, 3H), 3.80 (d, J = 0.64 Hz, 3H), 3.76 (s, 2H) 
13
C NMR (126 MHz, CDCl3)  174.3, 161.5, 160.0, 154.7, 130.9, 129.2, 124.1, 123.6, 123.0, 
114.6, 114.4, 70.6, 55.6, 55.5 
3-methoxyphenyl-4-phenylfuran-2(5H)-one (2b) 
Following general procedure B, the product was obtained as an orange solid in quantitative yield. 
1
H NMR (400 MHz, CDCl3)  7.36 - 7.42 (m, 3H), 7.30 - 7.36 (m, 4H), 6.86 - 6.93 (m, 2H), 5.15 
(s, 2H), 3.80 - 3.84 (m, 3H) 
13
C NMR (101 MHz, CDCl3)  174.0, 160.2, 155.0, 131.4, 130.8, 130.7, 129.2, 127.7, 122.5, 
114.4, 70.8, 55.5, 29.9 
LR-MS: 266.1 
General procedure C: 
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Butenolide and pyridine hydrochloride (10 eq) were heated with stirring at 220°C for two hours. 
After 2 hours, the reaction was cooled to room temperature and dissolved with ethyl acetate and 
3N HCl. The aqueous layer was extracted with ethyl acetate. The combined organic layers were 
washed with brine, dried over MgSO4, and concentrated by rotary evaporation to yield a dark 
brown solid in quantitative yield. This material was used without further purification. 
3,4-bis(4-hydroxyphenyl)furan-2(5H)-one (3a) 
1
H NMR (400 MHz, DMSO-d6)  10.05 (s, 1H), 9.67 (s, 1H), 7.19 - 7.27 (m, 2H), 7.09 - 7.15 
(m, 2H), 6.69 - 6.80 (m, 4H), 5.25 (s, 2H) 
3-hydroxyphenyl-4-phenylfuran-2(5H)-one (3b) 
1
H NMR (500 MHz, acetone-d6)  7.34 - 7.49 (m, 5H), 7.18 - 7.31 (m, 2H), 6.78 - 6.89 (m, 2H), 
5.27 (s, 2H) 
HR-MS (ESI): calculated for C16H12O3Na (M + Na)
+
: 275.0684; found: 275.0680 
General procedure D: 
Deprotected butenolide was dissolved in dry THF (0.2M) and cooled to -78°C with stirring. 
DIBAL-H (1.0M in CH2Cl2, 5 eq) was added dropwise. The bright red solution was stirred at -
78°C for 4 to 6 hours, until the reaction was complete, as judged by TLC. To monitor the 
reaction, an aliquot was taken with a syringe previously cooled to -78°C (using a flask filled with 
THF submerged in the dry ice / acetone bath), then quenched into a test tube at -78°C containing 
methanol. The reaction solution was transferred via cannula into rapidly stirring solution of 
methanol at -78°C. After this transfer was complete, the reaction mixture was warmed to 0°C in 
an ice bath. 10% H2SO4 was added to the reaction mixture, which briefly caused the reaction 
mixture to form a gel at the bottom of the flask. The organic solvents were removed by rotary 
evaporation. The aqueous residue was thoroughly extracted with ethyl acetate. The combined 
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organic layers were washed with brine and dried over Na2SO4. The solvent was removed by 
rotary evaporation. The crude reaction product was purified by flash chromatography. 
3,4-bis(4-hydroxyphenyl)furan (4a) 
Following general procedure D, the product was obtained as an off-white solid in 75% yield. 
1
H NMR (499 MHz, acetone-d6)  7.64 (s, 2H), 7.05 - 7.14 (m, 4H), 6.76 - 6.83 (m, 4H) 
13
C NMR (126 MHz, acetone-d6)  156.9, 140.3, 129.8, 125.9, 123.6, 115.5 
3-hydroxypheny-4-phenylfuran (4b) 
Following general procedure D, the product was obtained as an off-white solid in 47% yield. 
1
H NMR (500 MHz, CDCl3)  7.54 (d, J = 1.71 Hz, 1H), 7.51 (d, J = 1.72 Hz, 1H), 7.26 - 7.32 
(m, 3H), 7.21 - 7.25 (m, 2H), 7.07 - 7.13 (m, 2H), 6.74 - 6.80 (m, 2H), 4.84 (s, 1H) 
13
C NMR (126 MHz, CDCl3)  154.9, 140.8, 140.5, 132.3, 130.1, 128.7, 128.6, 127.2, 126.1, 
125.7, 124.8, 115.6 
HR-MS (ESI): calculated for C16H13O2 (M + H)
+
 : 237.0916; found: 237.0918 
General procedure E: 
Furan and dienophile (1.1 to 1.3 eq.) were combined in a 4mL vial. If both components were 
solids, drops of THF were added. The reaction was then heated to 95°C for 6 – 18 hr. The crude 
reaction mixture was purified by preparative TLC or flash chromatography. The product was 
then recrystallized from ethyl acetate/hexanes to yield pure product. 
5,6-Bis-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonic acid phenyl ester 
(OBHS) (5a) 
Following general procedure E, the product was obtained as a crystalline solid in 49% yield. 
1
H NMR (500 MHz, acetone-d6)  7.37 - 7.43 (m, 2H), 7.30 - 7.36 (m, 1H), 7.20 - 7.29 (m, 6H), 
6.78 - 6.86 (m, 4H), 5.65 (d, J = 1.29 Hz, 1H), 5.44 (dd, J = 1.29, 4.50 Hz, 1H), 3.77 (dd, J = 
4.50, 8.36 Hz, 1H), 2.41 (ddd, J = 4.50, 4.50, 12.10 Hz, 1H), 2.27 (dd, J = 8.36, 12.01 Hz, 1H) 
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HR-MS (ESI) calculated for C24H21O6S (M + H)
+
 : 437.1059; found: 437.1070 
Elemental Analysis: Theoretical for C24H20O6S: 66.04% C, 4.62% H; Found: 65.80% C, 4.59% 
H 
 (5/6)-(4-hydroxpyhenyl)-(6/5)-phenyl-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonic acid phenyl 
ester (5b) 
Following general procedure E, the product was obtained in 70% yield as a 4:1 ratio of 
regioisomers. 
1
H NMR (500 MHz, CDCl3)  (major isomer only) 7.27 - 7.36 (m, 7H), 7.16 - 7.23 (m, 4H), 
6.75 - 6.80 (m, 2H), 5.74 (d, J = 1.07 Hz, 1H), 5.43 (dd, J = 1.18, 4.39 Hz, 1H), 5.01 - 5.18 (m, 
1H), 3.59 (dd, J = 4.50, 8.36 Hz, 1H), 2.54 - 2.64 (m, 1H), 2.21 (dd, J = 8.58, 12.22 Hz, 1H) 
(5/6)-(4-hydroxyphenyl)-(6/5)-phenyl-7-oxabicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid 
diethyl ester (5c) 
Following general procedure E, the product was obtained in 50% yield. 
1
H NMR (400 MHz, CDCl3)  7.20 - 7.36 (m, 5H), 7.09 - 7.19 (m, 2H), 6.73 - 6.81 (m, 2H), 6.06 
(br. s., 1H), 5.46 - 5.53 (m, 2H), 4.12 - 4.25 (m, 4H), 3.14 (s, 2H), 1.23 - 1.36 (m, 6H) 
13
C NMR (101 MHz, CDCl3)  171.9, 171.7, 156.4, 141.7, 132.9, 129.3, 129.0, 128.3, 127.4, 
124.3, 116.0, 85.6, 61.7, 61.6, 48.9, 14.4, 14.4 
2-Benzenesulfonyl-(5/6)-(4-hydroxyphenyl)-(6/5)-phenyl-7-oxabicyclo[2.2.1]hept-5-ene (5d) 
Following general procedure E, the product was obtained in 45% yield as a 1.4:1 ratio of 
regioisomers. 
1
H NMR (500 MHz, CDCl3)  7.94 - 8.02 (m, 2H), 7.64 - 7.74 (m, 1H), 7.55 - 7.63 (m, 2H), 7.18 
- 7.24 (m, 3H), 7.08 - 7.17 (m, 2H), 7.00 - 7.07 (m, 1H), 6.72 - 6.77 (m, 1H), 6.66 - 6.71 (m, 1H), 
5.64 (d, J = 1.07 Hz, 1H), 5.61 (d, J = 1.07 Hz, 1H), 5.27 - 5.33 (m, 1H), 5.02 (s, 1H), 3.47 (dd, J 
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= 4.50, 8.36 Hz, 1H), 3.42 (dd, J = 4.29, 8.36 Hz, 1H), 2.41 (dd, J = 4.39, 12.11 Hz, 1H), 1.89 - 
2.03 (m, 1H) 
8,9-Bis-(4-hydroxyphenyl)-4-methyl-10-oxa-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione 
(5e) 
Following general procedure E, the product was isolated in 54% yield. 
1
H NMR (500 MHz, acetone-d6)  8.63 (br. s., 2H), 7.20 - 7.30 (m, 4H), 6.78 - 6.89 (m, 4H), 
5.37 - 5.39 (s, 2H), 3.19 - 3.26 (m, 2H), 2.86 - 2.92 (m, 2H) 
Elemental analysis: calculated 69.41% C, 4.72% H, 3.85% N; found: 68.28% C, 5.01% H, 3.67% 
N 
General procedure F 
Iodine was added in a three-neck flask with addition funnel to a solution of pyridine/ether (1:1 
v/v) slowly with vigorous stirring. 2-Cyclohexenone was added to the addition funnel. After the 
iodine had been added and stirred for 10 minutes, a few drops of the enone were added. The flask 
was placed in an ice bath, and the remainder of the enone was added dropwise. The solution 
stirred for 2 hours. At this time, the reaction mixture was poured onto 3N HCl and extracted with 
ether. The ether was washed again with 3N HCl, three times with 20% w/w aqueous sodium 
thiosulfate, and brine. The ether layer was dried over MgSO4 and evaporated on the rotary 
evaporator. 
2-iodo-2-cyclohexenone (11) 
Following general procedure F, the product was obtained as a yellow solid in 76%. 
1
H NMR (500 MHz, CDCl3)  7.75 (t, J = 4.40 Hz, 1H), 2.58 - 2.67 (m, 2H), 2.37 - 2.47 (m, 
2H), 2.01 - 2.12 (m, 2H) 
13
C NMR (126 MHz, CDCl3)  192.4, 159.8, 104.1, 37.5, 30.2, 23.1 
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HR-MS (EI): calculated for C6H7OI (M
+
): 221.9542; found: 221.9535 
2-iodo-2-cyclopentenone (6) 
Following general procedure F, the product was obtained as a yellow-orange solid in 63% yield. 
1
H NMR (499 MHz, CDCl3)  8.03 (t, J = 2.93 Hz, 1H), 2.76 - 2.82 (m, 2H), 2.49 - 2.55 (m, 2H) 
HR-MS (EI): calculated for C5HIOI (M
+
): 207.93855; found: 207.93917 
General procedure G 
Iodoenone 11 (2.168g, 9.76 mmol), 4-methoxyphenylboronic acid (1.5 eq.), silver oxide (1.5 
eq.), triphenylarsine (0.1eq.), and bis(benzonitrile)palladium(II) chloride (0.05 eq.) were 
combined in a round bottom flask. The flask was backfilled three times with argon before the 
addition of an 8:1 v:v THF:H2O solution. The reaction was purged with a balloon of argon for 10 
minutes, then stirred for an additional 45 minutes. Saturated NH4Cl was added, and the reaction 
stirred for 1 hour. The reaction mixture was filtered over Celite, and extracted three times with 
ether. The combined ether extracts were washed with brine, dried over MgSO4, and concentrated 
by rotary evaporation. The crude residue was purified by column chromatography (4:1 
hexanes:ethyl acetate). 
2-(4-methoxyphenyl)-2-cyclopentenone (7) 
Following general procedure G, the product was obtained as a white solid in 67% yield. 
1
H NMR (499 MHz, CDCl3)  7.74 (t, J = 2.93 Hz, 1H), 7.64 - 7.70 (m, 2H), 6.87 - 6.96 (m, 
2H), 3.82 (s, 3H), 2.67 - 2.72 (m, 2H), 2.56 - 2.60 (m, 2H) 
13
C NMR (126 MHz, CDCl3)  208.3, 159.9, 157.5, 142.9, 128.5, 124.5, 114.0, 55.5, 36.0, 26.3 
HR-MS (EI): calculated for C12H12O2 (M
+
): 188.08373; found: 188.08424 
2-(4-methxoyphenyl)-2-cyclohexenone (12) 
Following general procedure G, the product was obtained as a white solid in 85% yield. 
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1
H NMR (500 MHz, CDCl3)  7.21 - 7.28 (m, 2H), 6.98 (t, J = 4.29 Hz, 1H), 6.83 - 6.91 (m, 
2H), 2.55 - 2.62 (m, 2H), 2.48 - 2.55 (m, 2H), 2.10 (quin, J = 6.38 Hz, 2H) 
13
C NMR (126 MHz, CDCl3)  198.5, 159.3, 147.2, 140.0, 130.0, 129.2, 113.7, 55.5, 39.4, 26.9, 
23.2 
HR-MS (EI): calculated for C13H14O2 (M
+
): 202.0994; found: 202.1003 
6-(4-methoxyphenyl)-1,5-cyclohexadienyl trifluoromethanesulfonate (13) 
0.5 mL dry THF and NaHMDS (1.1 mL, 1.0M in THF, 1.1 mmol) were added to a dry round 
bottom flask. The solution was cooled to -78°C for 30 minutes with stirring. Cyclohexenone 12 
(200 mg, 0.99 mmol) was added as a solution in 1 mL THF. The solution turned light yellow. 
After 40 minutes of stirring at -78°, N-(5-chloro-2-pyridiyl)bis(trifluoromethanesulfonimide) 
(432 mg, 1.1 mmol) dissolved in 1 mL THF was added. The solution quickly turned red. The -
78°C bath was removed after 30 minutes, and the reaction gradually allowed to warm to room 
temperature over 45 minutes. The THF was removed by rotary evaporation; the residue was 
dissolved in 30 mL ether, washed twice with 10 mL of saturated aqueous NaHCO3, once with 10 
mL of brine, and dried over Na2SO4. Rotary evaporation yielded 292 mg (87%), which was used 
without further purification. Occasionally the material was purified by column chromatography 
(hexanes  10% EtOAc in hexanes), lowering the yield to ~60%. 
1
H NMR (499 MHz, CDCl3)  7.16 - 7.23 (m, 2H), 6.85 - 6.92 (m, 2H), 6.04 (t, J = 4.52 Hz, 
1H), 5.95 (t, J = 4.64 Hz, 1H), 3.83 (s, 3H), 2.29 - 2.48 (m, 4H) 
6-(4-methoxyphenyl)-1,5-cyclohexadien-2-ol TBS ether (14) 
A 1.0M solution of NaHMDS in THF (1.1 mL, 1.1 mmol, 1.0 eq.) and 0.5 mL THF were added 
to a dry round bottom flask. The solution was cooled to -78°C for 30 minutes. 12 was added as a 
solution in 1.5 mL dry THF. After 45 minutes of stirring at -78°C, TBSCl (166 mg, 1.1 mmol) 
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was added as a solution in 1 mL THF. The solution was stirred for 1 hour before the -78°C bath 
was removed and the reaction warmed to room temperature over 30 minutes. The THF was 
removed by rotary evaporation. The residue was dissolved in 25 mL ether and 7 mL saturated 
aqueous NaHCO3. The aqueous layer was extracted three times with 10 mL ether. The combined 
ether layers were washed with 10 mL brine, dried over Na2SO4, and concentrated on a rotary 
evaporator. The crude product was purified by column chromatography (5% EtOAc in hexanes) 
to yield 202 mg (64%) of a clear oil. 
1
H NMR (499 MHz, CDCl3)  7.20 - 7.25 (m, 2H), 6.80 - 6.85 (m, 2H), 5.90 - 5.99 (m, 1H), 5.09 
- 5.15 (m, 1H), 3.81 (s, 3H), 2.17 - 2.24 (m, 4H), 0.74 (s, 9H), -0.05 - -0.01 (m, 6H) 
13
C NMR (126 MHz, CDCl3)  158.7, 148.8, 138.4, 131.8, 130.2, 126.6, 113.2, 104.9, 55.5, 25.8, 
23.7, 22.4, 18.2, -4.6 
2-(4-methoxyphenyl)phenyl triflate(15) 
Diene triflate (39 mg, 0.12 mmol) 13, Pd(OAc)2 (2 mg, 0.075 eq.), 4-methoxyphenylboronic acid 
(21 mg, 0.14 mmol, 1.2 eq.) and potassium carbonate (20 mg, 0.14 mmol, 1.2 eq.) were 
combined in a round-bottomed flask. The flask was evacuated and backfilled three times with 
argon. Dry dioxane (0.500 mL) was added, and the reaction heated to 90°C for 24 hours. The 
crude residue was purified by preparative TLC (6:1 hexanes:EtOAc) to yield 18 mg (46%) of 15. 
1
H NMR (500 MHz, CDCl3)  7.50 - 7.59 (m, 4H), 7.42 (t, J = 7.61 Hz, 2H), 6.96 - 7.01 (m, 
2H), 3.86 (s, 3H) 
2-(4-methoxyphenyl)phenyl TBS ether (16) 
Cyclohexadiene 14 (22 mg, 0.069 mmol) and phenylvinyl sulfonate (15 mg, 0.083 mmol, 1.2 
eq.) were heated to 100°C in a 4 mL vial for 20 hours. After cooling to room temperature, the 
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residue was purified by preparative TLC (10% EtOAc in hexane) to yield a thin film. 
1
H NMR 
analysis indicated the starting material had oxidized to form 16. 
1
H NMR (500 MHz, CDCl3)  7.42 - 7.47 (m, 2H), 7.29 - 7.33 (m, 1H), 7.17 - 7.23 (m, 1H), 7.03 
(d, J = 1.22 Hz, 1H), 6.93 - 6.96 (m, 2H), 6.92 (dd, J = 0.98, 8.06 Hz, 1H), 3.86 (s, 3H), 0.84 - 
0.87 (m, 9H), -0.04 - -0.02 (m, 6H) 
2,3-bis(4-methoxyphenyl)-1,3-cyclopentadiene / 1,2-bis(4-methoxyphenyl)-1,3-
cyclopentadiene (8) 
4-bromoanisole (234mg, 1.25 mmol, 1.25 eq.) was dissolved in 1.5 mL THF and cooled to -
78°C. nBuLi (1.6M in hexanes, 0.75 mL, 1.2 mmol, 1.2 eq.) was added dropwise. The resulting 
solution stirred at the same temperature for 1 hour before the addition of 6 in 2 mL THF. The 
solution stirred at -78°C for an additional 30 minutes; during this time the solution turned 
yellow. The dry ice / acetone bath was removed, and the reaction mixture warmed to room 
temperature. After stirring at room temperature overnight, the reaction mixture was quenched 
with 8 mL of 2N HCl and stirred for 1 hour. The resulting solution was then extracted three 
times with 20 mL ether. The combined organic layers were washed with 20 mL brine, dried over 
Na2SO4, and concentrated. The crude residue was purified by column chromatography (9:1 
hexanes:EtOAc) to yield 40 mg (14%) of a white solid. 
1
H NMR (500 MHz, CDCl3)  (both isomers)7.26 - 7.30 (m, 2H), 7.18 - 7.24 (m, 2H), 7.07 - 
7.14 (m, 2H), 6.82 - 6.86 (m, 2H), 6.75 - 6.82 (m, 4H), 6.68 (td, J = 1.39, 5.36 Hz, 1H), 6.42 - 
6.48 (m, 2H), 3.82 (s, 3H), 3.80 (s, 3H), 3.79 (s, 3H), 3.49 (t, J = 1.39 Hz, 2H), 3.17 - 3.22 (m, 
1H) 
13
C NMR (126 MHz, CDCl3)  (both isomers) 158.7, 158.7, 158.3, 139.4, 139.2, 137.3, 131.5, 
131.0, 130.3, 130.0, 129.8, 129.6, 129.2, 114.0, 113.9, 113.5, 55.4, 55.4, 45.9, 40.3 
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HR-MS (EI): calculated for C19H18O2 (M
+
): 278.13068; found: 278.13131 
4-hydroxy-3,4-bis(4-methoxyphenyl)-2-cyclopentenone (9) 
In a round bottomed flask p-anisil (4.770 g, 17.6 mmol) and KOH (5.124 g, 91.3 mmol) were 
combined with 250 mL of absolute ethanol. The reaction mixture was heated to reflux; 10 mL 
acetone was added dropwise. The reaction stirred at reflux for an additional 2 hours. After 
cooling to room temperature the solvents were removed and replaced with 50 mL 3N HCl and 
125 mL EtOAc. The aqueous layer was extracted twice with 50 mL ethyl acetate. The combined 
organic layers were washed twice with 20 mL brine, dried over Na2SO4, and concentrated to 
yield adark red oil. This oil was purified by MPLC (hexanes/ethyl acetate gradient), yielding 
4.346g (79%) of a red oil, which turned into a foam upon drying under high vacuum. 
1
H NMR (500 MHz, CDCl3)  7.47 - 7.57 (m, 2H), 7.31 - 7.38 (m, 2H), 6.83 - 6.89 (m, 2H), 6.75 
- 6.82 (m, 2H), 6.58 (s, 1H), 3.78 (s, 3H), 3.78 (s, 3H), 2.77 - 3.02 (m, 3H) 
13
C NMR (126 MHz, CDCl3)  205.1, 173.8, 161.9, 159.0, 136.7, 131.5, 127.1, 126.1, 125.6, 
114.4, 114.3, 81.6, 56.9, 55.6, 55.5 
HR-MS (ESI): calculated for C19H19O4 (M + H)
+
: 311.1283; found: 311.1283 
3,4-bis(4-methoxyphenyl)-2-cyclopentenone (10) 
Hydroxycyclopentenone (2.04 g, 6.58 mmol) was dissolved in 40 mL MeCN. NaI (2.50 g, 16.67 
mmol) was added, followed by TMSCl (2 mL, 16.28 g, 16.20 mmol). The reaction mixture 
stirred at room temperature for 2 hours. The acetonitrile was removed and replaced with 50 mL 
EtOAc. 50 mL 20% w/w aqueous Na2S2O3 were added, and the layers separated. The aqueous 
layer was extracted twice with 50 mL EtOAc. The combined organic layers were dried over 
Na2SO4 and concentrated. The crude residue was purified by MPLC (hexanes/EtOAc gradient), 
yielding 1.378g (71%) of a brown foam. 
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1
H NMR (500 MHz, CDCl3) δ: 7.48 (d, J = 8.8 Hz, 2H), 7.06 (d, J = 8.6 Hz), 6.81 (m, 4H), 6.64 
(s, 1H), 4.54 (d, J = 7.3 Hz, 1H), 3.77 (s, 1H), 3.74 (s, 1H), 3.06 (dd, J1 = 7.3 Hz, J2 = 18.6 Hz, 
1H), 2.38 (d, J = 18.7 Hz) 
13
C NMR (125 MHz, CDCl3) δ: 208.49, 175.11, 161.85, 158.63, 135.11, 130.11, 128.26, 127.15, 
126.02, 126.02, 114.66, 114.34, 55.553, 55.429, 47.084, 46.212 
HR-MS (ESI): calculated for C19H19O3 (M + H)
+
 : 295.1334; found: 295.1335 
1,2-bis(4-methoxyphenyl)-1,3-cyclopentadiene (8) 
Cyclopentenone (548 mg, 1.86 mmol) dissolved in 15 mL dry THF. The solution was cooled to -
78°C for 25 minutes. DIBAL (4 mL of a 1.0M solution in hexanes, 4 mmol) was added 
dropwise. The dry ice bath was removed, and the reaction slowly warmed to room temperature 
over 1 hour. Drops of water were added to quench the excess DIBAL, followed by 10 mL 3N 
HCl. The solution was stirred for 2 hours; the THF was removed by rotary evaporation. The 
aqueous residue was extracted three times with 15 mL ether, washed with 15 mL brine, dried 
over Na2SO4, and concentrated to yield 453 mg (87%) of the diene product as an orange solid. 
Only the 1,2-diaryl isomer could be identified by NMR analysis. 
1
H NMR (500 MHz, CDCl3)  7.26 - 7.30 (m, 2H), 7.20 - 7.23 (m, 2H), 6.81 - 6.87 (m, 2H), 6.74 
- 6.80 (m, 2H), 6.68 (td, J = 1.42, 5.31 Hz, 1H), 6.46 (td, J = 1.50, 5.36 Hz, 1H), 3.82 (s, 3H), 
3.79 (s, 3H), 3.49 (t, J = 1.50 Hz, 2H) 
13
C NMR (126 MHz, CDCl3)  158.7, 158.4, 139.5, 139.2, 137.3, 131.5, 130.3, 130.1, 129.8, 
129.6, 114.0, 113.9, 55.4, 45.9 
1,2-bis(4-methoxyphenyl)-propenone (17) 
In a flame-dried flask methyltriphenylphosphonium bromide (2.68 g, 7.5 mmol, 2.5 eq.) and 
potassium tert-butoxide (842 mg, 7.5 mmol, 2.5 eq.) were combined. The flask was cooled in an 
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ice bath for several minutes before the addition of 8 mL of dry THF. After stirring at this 
temperature for 45 minutes, p-anisil (811 mg, 3 mmol) was added in 10 mL THF. The solution 
was allowed to warm to room temperature overnight. After quenching with 5 mL 1N HCl, the 
THF was removed by rotary evaporation. 10 mL water was added, and the reaction mixture 
extracted twice with 25 mL EtOAc. The combined organic layers were washed with 15 mL 
brine, dried over MgSO4 and concentrated by rotary evaporation. Purification of the residue by 
silica gel chromatography (3:1 hexanes : EtOAc) yielded 269 mg (33%) of the product as a 
yellow oil. 
1
H NMR (500 MHz, CDCl3)  7.89 - 7.96 (m, 2H), 7.32 - 7.39 (m, 2H), 6.88 - 6.93 (m, 2H), 6.84 
- 6.88 (m, 2H), 5.90 (s, 1H), 5.45 (s, 1H), 3.85 (s, 3H), 3.80 (s, 3H) 
13
C NMR (126 MHz, CDCl3)  196.9, 163.9, 160.0, 148.0, 132.7, 130.1, 129.9, 128.3, 117.2, 
114.2, 113.9, 55.7, 55.5 
2,3-bis(4-methoxyphenyl)-2,3-butanediol (18) 
In a dry round-bottom flask p-anisil (278 mg, 1.02 mmol) was dissolved in 10 mL dry THF, and 
cooled in an ice bath. To the resulting yellow solution was added 1.1 mL of a 3.0M solution of 
MeMgBr in ether (3.3 mmol, 3 eq.). The reaction warmed to room temperature for two hours, at 
which time the yellow color of the reaction disappeared. The reaction was quenched with 1N 
HCl, and concentrated by rotary evaporation. The residue was diluted with water and extracted 
with ethyl acetate. The combined organic extracts were dried over MgSO4 and concentrated by 
rotary evaporation. The crude residue was purified by MPLC (hexanes : EtOAc) to yield 186 mg 
of the product as a white solid in 77% yield.  
1
H NMR (500 MHz, CDCl3) (major isomer)  7.14 - 7.19 (m, 4H), 6.76 - 6.81 (m, 4H), 3.81 (s, 
6H), 2.17 - 2.34 (m, 2H), 1.58 (s, 6H) 
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13
C NMR (126 MHz, CDCl3) (major isomer)  158.6, 136.3, 128.3, 112.8, 78.7, 55.4, 25.4 
3,3-bis(4-methoxyphenyl)-2-butanone (19) 
Diol 19 (205 mg, 0.678 mmol) and Burgess’ reagent (355 mg, 1.492 mmol, 2.2 eq.) were 
dissolved in 5 mL toluene. The reaction mixture was heated to 50°C for 24 hours. The solvent 
was removed by rotary evaporation and the crude residue purified by MPLC (hexanes : EtOAc) 
to yield 83 mg (43%) of the product. 
1
H NMR (500 MHz, CDCl3)  7.09 - 7.17 (m, 4H), 6.86 - 6.92 (m, 4H), 3.83 (d, J = 0.73 Hz, 
6H), 2.12 (d, J = 0.49 Hz, 3H), 1.85 (s, 3H) 
3-(4-methoxyphenyl)thiophene (20) 
4-methoxyphenylboronic acid (966 mg, 6.4 mmol), 3.38 g K3PO4, and 224 mg PdCl2(PPh3)2 
combined in a round bottom flask with a stir bar. 864 mg 3-bromothiophene was transferred to 
the reaction flask with 25 mL dioxane. 5 mL water was added, and the reaction heated to 60°C 
overnight. After cooling to room temperature, the reaction was diluted with 60 mL ether and 60 
mL 1N NaOH. The aqueous layer was extracted three times with 50 mL ether, washed with 20 
mL brine, dried over Na2SO4, and concentrated on the rotary evaporator. The crude product was 
purified by column chromatography (3:1  2:1 hexanes:CH2Cl2), yielding 856 mg (85%) of a 
white solid. 
1
H NMR (499 MHz, CDCl3)  7.51 - 7.60 (m, 2H), 7.33 - 7.43 (m, 3H), 6.92 - 7.00 (m, 2H), 3.80 
- 3.89 (s, 3H) 
13
C NMR (126 MHz, CDCl3)  159.1, 142.2, 129.0, 127.8, 126.5, 126.3, 119.2, 114.4, 55.6 
HR-MS: calculated for C11H10OS (M
+
): 190.0452; found 190.0454 
2-bromo-3-(4-methoxyphenyl)thiophene (21)  
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Thiophene 20 (635 mg, 3.3 mmol) was dissolved in 20 mL CH2Cl2; the solution was cooled in an 
ice bath. N-bromosuccinimide (587 mg, 3.3 mmol) in 15 mL DMF added dropwise. The reaction 
mixture was allowed to warm to room temperature overnight. The reaction mixture was diluted 
with 100 mL brine, and the layers separated. The aqueous layer was extracted several times with 
CH2Cl2. The combined organic extracts were washed with 25 mL brine, dried over MgSO4, 
concentrated on the rotary evaporator, and further dried on a high vacuum at 40°C yielding 810 
mg (91%) of a clear oil, which was used without further purification. 
1
H NMR (500 MHz, CDCl3)  7.44 - 7.53 (m, 2H), 7.29 (d, J = 5.79 Hz, 1H), 7.01 (d, J = 5.57 
Hz, 1H), 6.93 - 6.99 (m, 2H), 3.85 (s, 3H) 
13
C NMR (126 MHz, CDCl3)  159.3, 141.1, 130.1, 129.3, 127.7, 126.0, 114.0, 108.1, 55.5 
2,3-bis(4-methoxyphenyl)thiophene (22) 
Bromothiophene 21 (746 mg, 2.77 mmol), 4-methoxyphenylboronic acid (631 mg, 4.15 mmol), 
K3PO4 (1.76g, 8.31 mmol), Pd(OAc)2 (31 mg, 0.13 mmol) and tri(tert-butyl)phosphonium 
tetrafluoroborate (80 mg, 0.28 mmol) were combined in a round bottom flask fitted with a 
condenser. The apparatus was evacuated and backfilled with argon three times, before dry 1,4-
dioxane (15 mL) were added. The reaction mixture was heated with stirring to 100° C for 16 
hours. After cooling to room temperature, 30 mL water and 30 mL ether were added. The 
resulting mixture was filtered over celite. The layers were separated, and the aqueous layer 
extracted three times with 30 mL ether. The combined organic layers were dried over MgSO4, 
and concentrated on the rotary evaporator. The crude residue was purified by column 
chromatography (40%  80% dichloromethane/hexane) to yield 505 mg (62%) of a white solid. 
1
H NMR (500 MHz, CDCl3)  7.16 - 7.30 (m, 5H), 7.11 (d, J = 5.15 Hz, 1H), 6.82 (dd, J = 7.18, 
8.68 Hz, 4H), 3.79 - 3.82 (m, 6H) 
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13
C NMR (126 MHz, CDCl3)  159.1, 158.7, 137.9, 137.3, 130.7, 130.6, 130.4, 129.4, 127.2, 
123.6, 114.1, 114.0, 55.5, 55.4 
5-bromo-3,4-bis(4-methoxyphenyl)thiophene-2-carboxylic acid (23) 
Thiophene 22 (440 mg, 1.49 mmol) dissolved in 7 mL dry THF. The reaction was then cooled to 
-78°C in a dry ice / acetone bath. nBuLi (1.0 mL, 1.6M in hexanes, 1.6 mmol) added dropwise. 
The reaction color changed from clear to green to blue over one hour. CO2 from a lecture bottle 
was passed through a drying tube cooled with dry ice / acetone into the reaction mixture. After a 
few seconds, the reaction mixture turned orange. The solution was stirred at this temperature for 
1.5 hours, before warming to room temperature. The THF was stripped, and 10 mL ethyl acetate 
added. 5 mL 1N HCl were added, which lowered the pH to <2. The aqueous layer was extracted 
three times with 10 mL ethyl acetate. The combined organic fractions were dried over Na2SO4 
and concentrated on the rotary evaporator. The crude residue was recrystallized from chloroform 
to yield 248 mg (50%) of the thiophene carboxylic acid. 
1
H NMR (500 MHz, CDCl3)  7.90 (s, 1H), 7.25 - 7.33 (m, 2H), 7.17 - 7.24 (m, 2H), 6.86 (dd, J 
= 5.86, 8.55 Hz, 4H), 3.77 - 3.88 (m, 6H) 
General procedure H 
Thiophene-2-carboxylic acid was suspended in dichloromethane and cooled to 0°C. Thionyl 
chloride (1.21eq.) was added dropwise; the ice bath was removed and the mixture stirred for 3 
hours. The solvent was removed, and the material dried on a high vacuum overnight. 
Dichloromethane was added, followed by aniline (1.1 eq.) and diisopropylethylamine (1.1 eq.).  
After stirring for 2 hours, the reaction mixture was poured into water and extracted exhaustively 
with dichloromethane. The combined organic layers were washed with water, brine, dried over 
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MgSO4, and concentrated on the rotary evaporator. The crude product was purified by column 
chromatography or preparative TLC (3:1 hexanes:EtOAc). 
4,5-bis(4-methoxyphenyl)-N-phenylthiophene-2-carboxamide (24a) 
Following general procedure H, the crude product was isolated in 89% yield, and used without 
further purification. 
1
H NMR (400 MHz, CDCl3)  7.98 (s, 1H), 7.56 - 7.68 (m, 3H), 7.32 (t, J = 7.93 Hz, 2H), 7.05 - 
7.26 (m, 6H), 6.79 (dd, J = 1.10, 8.91 Hz, 4H), 3.77 (d, J = 2.20 Hz, 6H) 
4,5-bis(4-methoxyphenyl)-N-(4-fluorophenyl)thiophene-2-carboxamide (24b) 
Following general procedure H, the crude product was isolated in 46% yield, and used without 
further purification. 
1
H NMR (499 MHz, CDCl3)  8.02 (br. s., 1H), 7.62 (s, 1H), 7.59 (dd, J = 4.76, 7.69 Hz, 2H), 
7.22 (d, J = 7.81 Hz, 2H), 7.16 (d, J = 7.81 Hz, 2H), 7.03 (t, J = 8.18 Hz, 2H), 6.81 (d, J = 8.30 
Hz, 4H), 3.80 (s, 6H) 
4,5-bis(4-methoxyphenyl)-N-(3-fluorophenyl)thiophene-2-carboxamide (24c) 
Following general procedure H, the product was isolated in 57% yield after column 
chromatography. 
1
H NMR (499 MHz, CDCl3)  7.97 (s, 1H), 7.58 - 7.66 (m, 2H), 7.28 - 7.32 (m, 2H), 7.21 - 7.25 
(m, 2H), 7.15 - 7.20 (m, 2H), 6.80 - 6.84 (m, 4H) 
4,5-bis(4-methoxyphenyl)-N-(3-chloro-2-methylphenyl)thiophene-2-carboxamide (24d) 
Following general procedure H, the product was isolated in 69% yield after column 
chromatography. 
1
H NMR (499 MHz, CDCl3)  7.97 (s, 1H), 7.58 - 7.66 (m, 2H), 7.28 - 7.32 (m, 2H), 7.21 - 7.25 
(m, 2H), 7.15 - 7.20 (m, 2H), 6.80 - 6.84 (m, 4H) 
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General procedure I 
Thiophene carboxamide 25 was dissolved in dichloromethane and cooled to 0°C. Boron 
tribromide (1.0M in dichloromethane, 6 – 8 eq.) was added dropwise. The product was placed in 
a -20°C freezer overnight. After warming to room temperature, the reaction was quenched with 
methanol. The solvents were evaporated, and the residue purified by preparative TLC. 
4,5-bis(4-hydroxyphenyl)-N-phenylthiophene-2-carboxamide (25a) 
Following general procedure I, the product was isolated in 50% yield after preparative TLC (2:1 
hexanes:EtOAc, 1:1 hexanes:EtOAc) 
1
H NMR (499 MHz, acetone-d6)  8.44 - 8.79 (m, 1H), 7.93 (s, 1H), 7.77 - 7.87 (m, 2H), 7.36 
(dd, J = 7.57, 8.55 Hz, 2H), 7.19 - 7.24 (m, 2H), 7.14 - 7.18 (m, 2H), 7.09 - 7.14 (m, 1H), 6.81 - 
6.86 (m, 4H)
  
13
C NMR (126 MHz, acetone-d6)  160.1, 157.9, 157.0, 143.3, 139.4, 138.0, 137.3, 131.4, 130.6, 
130.3, 128.9, 127.5, 123.9, 120.2, 115.8, 115.6 
4,5-bis(4-hydroxyphenyl)-N-(4-fluorophenyl)thiophene-2-carboxamide (25b) 
Following general procedure I, the product was isolated in 47% yield after preparative TLC (2:1 
hexanes : EtOAc, 1:1 hexanes : EtOAc) 
1
H NMR (500 MHz, acetone-d6)  9.57 (s, 1H), 8.67 (br. s., 1H), 8.50 (br. s., 1H), 7.89 (s, 1H), 
7.79 - 7.86 (m, 2H), 7.20 (d, J = 8.58 Hz, 2H), 7.08 - 7.16 (m, 4H), 6.79 - 6.85 (m, 4H) 
13
C NMR (126 MHz, acetone-d6)  160.0, 158.2, 160.0, 157.0, 143.4, 138.0, 137.0, 135.6, 131.5, 
130.6, 130.2, 127.5, 125.2, 122.0, 115.7, 115.4, 115.3  
4,5-bis(4-hydroxyphenyl)-N-(3-fluorophenyl)thiophene-2-carboxamide (25c) 
Following general procedure I, the product was isolated in 26% yield after preparative TLC (1:1 
hexanes:EtOAc) 
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1
H NMR (500 MHz, acetone-d6)  9.31 - 9.49 (m, 1H), 8.59 - 9.03 (m, 1H), 7.93 (s, 1H), 7.48 (d, 
J = 7.72 Hz, 1H), 7.32 (d, J = 7.72 Hz, 1H), 7.12 - 7.26 (m, 5H), 6.81 (dd, J = 6.75, 8.68 Hz, 
4H), 2.37 (s, 3H) 
4,5-bis(4-hydroxyphenyl)-N-(3-chloro-2-methylphenyl)thiophene-2-carboxamide (25d) 
Following general procedure I, the product was isolated in 44% yield after preparative TLC (1:1 
hexanes:EtOAc) 
1
H NMR (500 MHz, acetone-d6)  9.29 - 9.50 (m, 1H), 8.50 - 9.05 (m, 1H), 7.93 (s, 1H), 7.48 (d, 
J = 7.93 Hz, 1H), 7.32 (d, J = 7.29 Hz, 1H), 7.22 - 7.27 (m, 1H), 7.12 - 7.22 (m, 4H), 6.77 - 6.85 
(m, 4H), 2.37 (s, 3H) 
2,3-bis(4-methoxyphenyl)-2-oxopropionitrile (26) 
Methyl 4-methoxybenzoate (1..83g, 11 mmol)  sodium hydride (880 of a 60% dispersion in 
mineral oil, 528 mg NaH, 22 mmol) were suspended in 50 mL dry THF in a 3-neck flask fitted 
with a condenser, septum and glass stopper. 4-methoxyphenylacetonitrile (1.47g, 10 mmol) was 
added via syringe to the stirring reaction mixture. The reaction mixture was refluxed overnight; 
after this time the reaction was cooled to room temperature. The reaction was quenched with 10 
mL H2O and the THF removed by rotary evaporation. The aqueous layer was extracted three 
times with 25 mL ether. The aqueous layer was acidified with 15 mL 1N HCl and extracted three 
times with 25 mL ethyl acetate. The combined organic layers were dried over MgSO4 and 
concentrated by rotary evaporation to yield 1.88g (67%) of a yellow syrup. 
1
H NMR (499 MHz, CDCl3)  7.37 - 7.45 (m, 3H), 7.21 - 7.34 (m, 7H), 6.70 - 6.80 (m, 2H), 5.91 
- 6.01 (m, 3H), 3.82 (s, 3H), 3.81 (s, 3H) 
13
C NMR (101 MHz, CDCl3)  187.7, 164.6, 160.2, 131.9, 129.6, 126.6, 122.8, 117.3, 115.2, 
114.4, 55.8, 55.6, 45.9 
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HR-MS (ESI): calculated for C17H15NO3Na (M + Na)
+
: 304.0950; found: 304.0949 
5-amino-3,4-bis(4-methoxyphenyl)-1H-pyrazole (27) 
Ketonitrile 26 (1.29 g, 4.57 mmol), 25 mL ethanol and 1.4 mL concentrated HCl were heated 
with stirring to 80°C. 711 μL (22.8 mmol) hydrazine hydrate was added dropwise. The reaction 
mixture was stirred for 16 hr. After cooling to room temperature, the solvent was removed on a 
rotary evaporator. The residue was partitioned in 5 mL water and the pH was adjusted to 7 with 
approximately 15 mL saturated NaHCO3. The water was extracted three times with 15 mL ethyl 
acetate. The combined organic layers were washed with 10 mL brine, 10 mL water, dried over 
Na2SO4 and concentrated on a rotary evaporator. The residue was purified by flash 
chromatography (10% MeOH / CHCl3) to yield 1.08 g (80%) of a white solid. 
1
H NMR (500 MHz, acetone-d6)  7.27 - 7.34 (m, 2H), 7.13 - 7.21 (m, 2H), 6.89 - 6.94 (m, 2H), 
6.83 - 6.88 (m, 2H), 4.13 (br. s., 2H), 3.80 (s, 3H), 3.79 (s, 3H)
 
2,3-bis(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-5(4H)-one (28) 
Aminopyrazole (880 mg, 2.98 mmol) and ethyl 3-ethoxyacrylate (650 mg, 4.5 mmol) were 
dissolved in 30 mL of DMF. Cesium carbonate (1.50g, 4.5 mmol) was added. The reaction 
mixture, which turned dark red, was heated to 110° C for 4 hours. After cooling to room 
temperature, the reaction was neutralized with acetic acid (10 mL). The quenched reaction 
mixture was diluted with 150 mL of brine and extracted twice with 50 mL of ethyl acetate. The 
combined organic layers were washed twice with 15 mL brine, dried over Na2SO4, and 
concentrated in vacuo to yield a brick red solid. The crude product was purified by passage 
through a plug of silica gel (5% MeOH in dichloromethane), yielding 518 mg (50%) of a dark 
red solid. 
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1
H NMR (499 MHz, DMSO-d6)  8.38 (d, J = 7.81 Hz, 1H), 7.30 (d, J = 8.55 Hz, 2H), 7.12 (d, J 
= 8.30 Hz, 2H), 6.91 (d, J = 8.55 Hz, 2H), 6.82 (d, J = 8.55 Hz, 2H), 5.94 (d, J = 7.81 Hz, 1H), 
3.75 (s, 3H), 3.70 (s, 3H) 
5-chloro-2,3-bis(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidine (29) 
Pyrazolo[1,5-a]pyrimidinone (292 mg, 0.84 mmol)  and 6 mL of toluene were combined in a 
round-bottomed flask. Phosphorous oxychloride (516 mg, 313 μL, 3.36 mmol) was added, and 
the reaction mixture was heated to 110°C.  After stirring at this temperature for 3 hours, the 
mixture was cooled to room temperature. After the addition of 15 mL ethyl acetate, the reaction 
was quenched dropwise with 15 mL saturated NaHCO3. The layers were separated and the 
aqueous layer extracted three times with 15 mL ethyl acetate. The combined organic layers were 
washed with 10 mL brine, dried with MgSO, and concentrated. The crude product was purified 
by column chromatography (2:1 hexanes:EtOAc), yielding 155 mg (50%). 
1
H NMR (500 MHz, acetone-d6)  8.95 (d, J = 7.20 Hz, 1H), 8.14 (s, 1H), 7.56 - 7.63 (m, 2H), 
7.35 - 7.44 (m, 2H), 7.05 (d, J = 7.20 Hz, 1H), 6.93 - 7.02 (m, 4H), 3.86 (s, 3H), 3.85 (s, 3H) 
13
C NMR (126 MHz, acetone-d6)  160.5, 159.2, 154.5, 149.9, 137.4, 131.3, 130.2, 125.5, 123.8, 
114.1, 114.0, 109.1, 54.9, 54.9 
HR-MS (ESI): calculated for C20H17N3O2Cl (M+H)
+
: 366.1.009; found 366.1004 
General procedure J 
Chloropyrazole, phenol (1.5 eq.), and potassium carbonate (1.5 eq.) were combined in DMF 
(0.2M with respect to chloropyrazole). The reaction mixture was heated with stirred at 80° C 
overnight. After cooling to room temperature, the reaction mixture was diluted with brine and 
extracted several times with ethyl acetate. The combined organic layers were washed with brine, 
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dried over Na2SO4, and concentrated. The crude residue was purified by column chromatography 
or preparative TLC (hexanes / ethyl acetate). 
2,3-bis(4-methoxyphenyl)-5-phenoxypyrazolo[1,5-a]pyrimidine (30a) 
Following general procedure J, the product was isolated in 94% yield and used without further 
purification. 
1
H NMR (499 MHz, CDCl3)  8.54 (d, J = 7.32 Hz, 1H), 7.54 - 7.61 (m, 2H), 7.39 - 7.48 (m, 
2H), 7.32 - 7.38 (m, 2H), 7.25 - 7.31 (m, 3H), 6.87 - 6.95 (m, 2H), 6.74 - 6.83 (m, 2H), 6.50 (d, J 
= 7.32 Hz, 1H), 3.85 (s, 3H), 3.80 (s, 3H) 
13
C NMR (126 MHz, CDCl3)  160.9, 160.1, 158.2, 154.7, 144.6, 137.5, 130.5, 130.4, 129.6, 
125.6, 121.8, 114.1, 113.8, 106.9, 99.7, 55.5, 55.4 
HR-MS: calculated for C26H22N3O3 (M + H
+
): 424.1661; found: 424.1669 
2,3-bis(4-methoxyphenyl)5-(4-fluorophenyl)pyrazolo[1,5-a]pyrimidine (30b) 
Following general procedure J, the product was solated in 89% yield and used without further 
purification. 
1
H NMR (500 MHz, CDCl3)  8.54 (d, J = 7.29 Hz, 1H), 7.48 - 7.60 (m, 2H), 7.28 - 7.36 (m, 
2H), 7.20 - 7.25 (m, 2H), 7.03 - 7.13 (m, 2H), 6.87 - 6.94 (m, 2H), 6.75 - 6.82 (m, 2H), 6.49 (d, J 
= 7.29 Hz, 1H), 3.83 (s, 3H), 3.80 (s, 3H) 
General procedure K 
The crude pyrazolopyrimidines 30 were dissolved in CH2Cl2 and cooled on ice. Boron trifluoride 
complexed with methyl sulfide was added (50 eq.), and the reaction mixture warmed to room 
temperature overnight. The reaction was quenched with methanol, and the solvents evaporated. 
The residue was neutralized with saturated NaHCO3, then extracted several times with ethyl 
acetate. The combined organic layers were washed with brine, dried over MgSO4 and 
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concentrated. The crude product was purified by column chromatography (1:1 hexanes:EtOAc) 
to yield the product. 
2,3-bis(4-hydroxyphenyl)-5-phenoxypyrazolo[1,5-a]pyrimidine (31a) 
Following general procedure K, the product was obtained in 49% yield as an off-white solid. 
1
H NMR (500 MHz, acetone-d6)  8.84 (d, J = 7.32 Hz, 1H), 8.65 (br. s, 1H), 8.30 (br. s, 1H), 
7.48 (d, J = 8.55 Hz, 4H), 7.33 - 7.40 (m, 2H), 7.26 - 7.32 (m, 1H), 7.23 (d, J = 8.79 Hz, 2H), 
6.87 (d, J = 8.79 Hz, 2H), 6.66 - 6.77 (m, 3H) 
HR-MS (ESI): calculated for C24H18N3O5 (M+H)
+
: 396.1348; found: 396.1347 
2,3-bis(4-hydroxyphenyl)-5-(4-fluorophenoxy)pyrazolo[1,5-a]pyrimidine (31b) 
Following general procedure K, the product was obtained in 57% yield as an off-white solid 
1
H NMR (499 MHz, acetone-d6)  8.83 (d, J = 7.32 Hz, 1H), 8.59 (br. s., 1H), 8.25 (br. s., 1H), 
7.47 (d, J = 8.30 Hz, 2H), 7.33 - 7.42 (m, 2H), 7.15 - 7.30 (m, 4H), 6.86 (d, J = 8.30 Hz, 2H), 
6.67 - 6.78 (m, 3H) 
13
C NMR (126 MHz, acetone-d6)  ppm 161.0, 158.0 (d, J=5.4 Hz), 156.0, 154.2, 144.3, 138.4, 
130.7, 130.3, 125.2, 123.7 (d, J=8.3 Hz), 123.4, 115.9 (d, J=22.9 Hz), 115.3, 115.0, 106.7, 99.6 
HR-MS (ESI): calculated for C24H17N3O3 (M+H)
+
: 414.1254; found: 414.1257 
1-iodo-3-isopropoxybenzene (32a) 
3-iodophenol (4.856 g, 22.05 mmol) and K2CO3 (4.671 g, 33.80 mmol) were combined in a 
round bottom flask with 45 mL DMF. 2-bromopropane (4.0 mL, 5.244g, 42.6 mmol) was added 
and the reaction mixture heated to 75°C for 24 hours. After cooling to room temperature the 
reaction was poured into half-saturated brine and extracted with hexanes (3 x 100 mL). The 
combined organic layers were washed with 50 mL brine, dried over MgSO4 and concentrated in 
vacuo to yield 5.132g (89%) of a clear oil. 
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1
H NMR (499 MHz, CDCl3)  7.18 - 7.32 (m, 2H), 6.99 (t, J = 8.18 Hz, 1H), 6.81 - 6.90 (m, 
1H), 4.52 (spt, J = 6.02 Hz, 1H), 1.34 (d, J = 6.10 Hz, 6H) 
13
C NMR (126 MHz, CDCl3)  158.8, 131.0, 129.8, 125.3, 115.6, 94.6, 70.5, 22.2 
HR-MS (ESI): calc’d for C9H11OI (M+H)
+
: 261.98455; found: 261.98550 
1-iodo-3-(tert-butyldimethylsiloxy)benzene (32b) 
3-iodophenol (4.40 g, 20 mmol), TBSCl (4.52 g, 30 mmol, 1.5 eq.), and imidazole (2.72 g, 40 
mmol, 2.0 eq.) were combined with 40 mL of DMF. The reaction mixture was stirred at room 
temperature for 3 hours. The reaction mixture was diluted with 200 mL of saturated NaHCO3, 
and extracted with hexanes (3 x 100 mL). The combined organic extracts were washed with 
brine (2 x 100 mL), dried over MgSO4 and concentrated by rotary evaporation to yield 6.22 
(93%) of a clear oil, which was used without further purification. 
1
H NMR (500 MHz, CDCl3)  7.27 - 7.34 (m, 1H), 7.23 (t, J = 1.82 Hz, 1H), 6.95 (t, J = 8.04 
Hz, 1H), 6.81 (td, J = 1.18, 8.15 Hz, 1H), 0.99 (s, 9H), 0.21 (s, 6H)
 
13
C NMR (126 MHz, CDCl3)  156.5, 130.9, 130.7, 129.7, 119.7, 94.4, 25.9, 18.4, -4.2 
General procedure L 
Aryl iodide was dissolved in DMF. NBS (1.1 eq.) was added portionwise to the stirring solution, 
which turned yellow. The solution stirred for 18 hours, before being diluted with 50% brine. The 
aqueous layer was extracted with hexanes, dried over MgSO4, and concentrated to yield product. 
1-bromo-2-iodo-4-isopropoxybenzene (33a) 
Following general procedure L, and purification by column chromatography (10% EtOAc in 
hexanes), the product was obtained as a yellow oil in 73% yield. 
1
H NMR (499 MHz, CDCl3)  7.46 (d, J = 8.79 Hz, 6H), 7.39 (d, J = 2.69 Hz, 6H), 6.75 (dd, J = 
2.93, 8.79 Hz, 7H), 4.48 (spt, J = 5.86, 1H), 1.33 (d, J = 5.86 Hz, 6H) 
90 
 
13
C NMR (126 MHz, CDCl3)  157.3, 132.9, 127.7, 120.1, 117.8, 101.3, 70.9, 22.1 
HRMS (EI): calc’d for C9H10OIBr (M
+
): 339.89671; found: 339.89600 
1-bromo-2-iodo-4-(tert-butyldimethylsilyloxy)benzene (33b) 
Following general procedure L, the product was obtained as clear oil in 70% yield, following 
column chromatography (5% EtOAc/hexanes). 
1
H NMR (499 MHz, CDCl3)  ppm 7.44 (d, J=8.8 Hz, 1 H), 7.37 (d, J=2.9 Hz, 1 H), 6.70 (dd, 
J=8.7, 2.8 Hz, 4 H), 0.98 (s, 9 H), 0.21 (s, 6 H) 
13
C NMR (126 MHz, CDCl3)  ppm 155.2, 132.8, 132.1, 121.7, 121.3, 101.1, 25.8, 18.4, -4.3 
4-bromo-3-iodoanisole (33c) 
Following general procedure L, the product was obtained in 84% yield as a yellow oil, and used 
without further purification. 
1
H NMR (500 MHz, CDCl3)  ppm 7.46 (d, J=9.0 Hz, 1 H), 7.38 (d, J=3.0 Hz, 1 H), 6.76 (dd, 
J=8.8, 3.0 Hz, 1 H), 3.76 (s, 3 H) 
13
C NMR (126 MHz, CDCl3) d ppm 158.9 (s), 132.9 (s), 125.6 (s), 120.5 (s), 116.3 (s), 101.3 (s), 
55.9 (s) 
HRMS (EI): calc’d for C7H6BrOI (M
+
): 311.86358; found: 311.86470 
1-bromo-4-isopropoxy-2-((4-methoxyphenyl)ethynyl)benzene (34) 
Aryl iodide 33 (1.667 g, 4.74 mmol), 4-ethynylanisole (632 mg, 4.782 mmol), CuI (70 mg, 0.368 
mmol) and bis(triphenylphosphine)palladium(II) chloride (60 mg, 0.085 mmol) were combined 
in a round bottom flask and fitted with a septum. The reaction mixture was backfilled three times 
with argon before the addition of dry Et3N. Using liquid nitrogen the reaction mixture was 
further freeze-pump-thaw degassed. After the last cycle the flask was filled with argon and 
warmed to room temperature before being heated to 50°C for 5 hours. The reaction mixture was 
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diluted with 50 mL 50% saturated aqueous NH4Cl and extracted twice with 100 mL ethyl 
acetate. The combined organic layers were washed with 25 mL brine, dried over MgSO4, and 
concentrated in vacuo to yield a dark yellow oil. The crude product was purified by flash 
chromatography (hexanes  10% EtOAc/hexanes) to yield 1.363 g (83%) of the 
bromoarylalkyne. 
1
H NMR (500 MHz, CDCl3)  7.52 (d, J = 8.58 Hz, 2H), 7.45 (d, J = 8.79 Hz, 1H), 7.06 (d, J = 
2.79 Hz, 1H), 6.89 (d, J = 8.58 Hz, 2H), 6.72 (dd, J = 2.79, 8.79 Hz, 1H), 4.51 (d, J = 6.22 Hz, 
1H), 3.83 (s, 3H), 1.33 (d, J = 6.00 Hz, 6H) 
13
C NMR (126 MHz, CDCl3)  160.2, 157.0, 133.4, 133.3, 126.4, 119.9, 118.2, 116.1, 115.2, 
114.3, 93.9, 87.2, 70.7, 55.6, 22.2 
HRMS (ESI): calc’d for C18H18O2: 345.0490 (M+H
+
); found: 345.0490 
1-thiomethyl-4-isopropoxy-2-((4-methoxyphenyl)ethynyl)benzene (35) 
Aryl bromide 34 (3.31 g, 9.59 mmol) was dissolved in 75 mL dry THF and cooled to -78°C. 
nBuLi (1.6M in hexanes, 12 mL, 19.2 mmol, 2 eq.) was added dropwise over 5 minutes. The 
resulting orange solution was stirred at the same temperature for 1 hour. Methyl disulfide (1.984 
g, 21 mmol, 2.2 eq.) was added. The solution turned black briefly before returning to an orange 
color. The solution was stirred at -78°C for 1.5 hours, before warming to room temperature. The 
reaction mixture was adsorbed onto Celite, dried under vacuum, and purified by MPLC using 
hexanes / ethyl acetate to yield 1.658 g of a thick yellow oil in 55% yield. 
1
H NMR (499 MHz, CDCl3)  7.49 - 7.58 (m, 2H), 7.17 (d, J = 8.55 Hz, 1H), 7.06 (d, J = 2.69 
Hz, 1H), 6.88 - 6.93 (m, 2H), 6.86 (dd, J = 2.81, 8.67 Hz, 1H), 4.53 (d, J = 6.35 Hz, 1H), 3.84 (s, 
3H), 2.50 (s, 3H), 1.34 (d, J = 6.10 Hz, 6H) 
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13
C NMR (126 MHz, CDCl3)  160.0, 156.0, 133.3, 131.9, 128.5, 124.4, 119.6, 117.7, 115.6, 
114.2, 95.3, 86.3, 70.7, 55.5, 22.2, 16.8 
HR-MS (ESI): calc’d for C19H21O2S (M+H)
+
: 313.1262; found: 313.1262 
3-iodo-5-isopropoxy-2-(4-methoxyphenyl)benzo[b]thiophene (36) 
Alkyne 35 (1.600 g, 5.12 mmol) was dissolved in dichloromethane (45 mL). Iodine (1.446 g, 
5.67 mmol, 1.1 eq.) was added in portions to the stirring solution. The reaction was allowed to 
stir for an additional 45 minutes. 80 mL of a 20% w/w Na2S2O4 solution was added, followed by 
extraction with dichloromethane (2 x 150 mL). The combined organic extracts were washed with 
50 mL brine, dried over MgSO4, and concentrated to yield 84% of a light brown solid. The 
product was pure enough for further reactions. If necessary the product could be purified by 
column chromatography (5% EtOAc/hexanes). 
1
H NMR (499 MHz, CDCl3)  7.58 - 7.67 (m, 3H), 7.31 (d, J = 2.44 Hz, 1H), 6.98 - 7.04 (m, 
3H), 4.71 (spt, J = 6.10 Hz, 1H), 3.89 (s, 3H), 1.43 (d, J = 6.10 Hz, 6H) 
13
C NMR (126 MHz, CDCl3)  160.3, 156.9, 143.5, 143.4, 131.4, 131.2, 127.3, 123.1, 117.2, 
114.1, 111.7, 78.8, 70.9, 55.6, 22.3 
HRMS (ESI): calc’d for C18H18O2SI (M+H)
+
: 425.0072; found 425.0075 
5-isopropoxy-2,3-bis(4-methoxyphenyl)benzo[b]thiophene (37) 
Benzo[b]thiophene iodide 36 (1.338 g, 3.15 mmol), 4-methoxyphenylboronic acid (720 mg, 4.74 
mmol, 1.5 eq), cesium carbonate (2.33 g, 7.15 mmol, 2.27 eq.) and PdCl2(dppf) (208 mg, 0.25 
mmol, 7.9 eq.) were combined in a dry round-bottom flask fitted with a condenser and septum. 
The reaction apparatus was backfilled with argon three times. 5 mL dry dioxane was added 
through the septum and placed in a preheated 110°C oil bath. The reaction mixture refluxed for 
1.5 hours, before cooling to room temperature. 25 mL saturated NH4Cl was added. The aqueous 
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layer was extracted with ethyl acetate (3 x 25 mL), dried over MgSO4 and concentrated. The 
crude residue was purified by column chromatography (15% EtOAc in hexanes) to yield 1.020 g 
(80%) of a yellow solid. 
1
H NMR (500 MHz, CDCl3)  7.70 (d, J = 8.58 Hz, 1H), 7.22 - 7.26 (m, 4H), 7.05 (d, J = 2.36 
Hz, 1H), 6.97 (dd, J = 2.47, 8.68 Hz, 1H), 6.92 - 6.96 (m, 2H), 6.75 - 6.81 (m, 2H), 4.51 (spt, J = 
6.04 Hz, 1H), 3.85 - 3.87 (m, 3H), 3.79 (s, 3H), 1.31 (d, J = 6.00 Hz, 6H) 
13
C NMR (126 MHz, CDCl3)  159.3, 159.0, 156.0, 142.6, 140.5, 132.0, 131.7, 131.2, 130.9, 
128.2, 127.2, 122.9, 115.9, 114.4, 114.0, 109.3, 70.7, 55.5, 55.4, 22.3 
HR-MS (ESI): calc’d for C25H25O3S (M+H)
+
: 405.1524; found: 405.1525 
5-hydroxy-2,3-bis(4-methoxyphenyl)benzo[b]thiophene (38) 
Benzo[b]thiophene 37 (787 mg, 1.95 mmol) was dissolved in CH2Cl2. AlCl3 (400 mg, 2.99 
mmol, 1.5 eq) was added, and the reaction stirred for 48 hours. The reaction was quenched with 
methanol, loaded onto Celite, and purified by MPLC (hexanes/EtOAc gradient) to yield 481 mg 
(68%) of a yellow foam. 
1
H NMR (499 MHz, CDCl3)  7.69 (d, J = 8.55 Hz, 1H), 7.17 - 7.32 (m, 4H), 7.00 (d, J = 2.20 
Hz, 1H), 6.89 - 6.97 (m, 3H), 6.80 (d, J = 8.55 Hz, 2H), 5.04 (br. s., 1H), 3.86 (s, 3H), 3.81 (s, 
3H) 
13
C NMR (126 MHz, CDCl3)  159.4, 159.0, 153.6, 142.8, 140.9, 131.7, 131.1, 130.9, 128.2, 
127.1, 123.1, 114.4, 114.3, 114.1, 108.5, 55.5, 55.5 
2,3-bis(4-methoxyphenyl)benzo[b]thiophene-5-tosylate (39) 
38 (392 mg, 1.08 mmol) and tosyl chloride (224 mg, 1.17 mmol, 1.09 eq.) were dissolved in 3 
mL dichloromethane. 1 mL pyridine was added, and the reaction stirred overnight. The reaction 
was diluted with 10 mL saturated NH4Cl and extracted three times with 10 mL of 
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dichloromethane. The combined extracts were dried over MgSO4 and concentrated by rotary 
evaporation. The crude residue was purified by silica gel chromatography (40% EtOAc in 
hexanes) to yield 284 mg (51%) of 39 as an off-white powder. 
1
H NMR (400 MHz, CDCl3)  7.58 - 7.77 (m, 3H), 7.27 (d, J = 8.06 Hz, 2H), 7.19 (d, J = 8.55 
Hz, 2H), 6.93 - 7.06 (m, 4H), 6.82 - 6.89 (m, 2H), 6.76 (d, J = 8.79 Hz, 2H), 3.80 - 3.93 (m, 3H), 
3.76 (s, 3H), 2.38 - 2.52 (m, 3H) 
13
C NMR (101 MHz, CDCl3)  159.6, 159.1, 147.4, 145.4, 142.0, 141.6, 137.1, 132.5, 131.9, 
131.4, 130.9, 129.9, 128.9, 127.1, 126.4, 123.1, 119.3, 116.8, 114.4, 114.1, 55.4, 22.0 
2,3-bis(4-methoxyphenyl)benzo[b]thiophene-5-triflate (40) 
38 (397 mg, 1.09 mmol) was dissolved in 1 mL dry pyridine. The reaction was cooled to 0°C for 
several minutes before triflic anhydride (325 mg, 1.18 mmol, 1.09 eq.) was added dropwise. The 
solution was stirred at this temperature for 40 minutes. The reaction mixture was diluted with 30 
mL of ethyl acetate and washed sequentially with saturated NH4Cl (10 mL) and brine (10 mL). 
The organic layer was dried over MgSO4 and concentrated. The crude residue was purified by 
silica gel chromatography (15% EtOAc in hexane) to yield 374 mg (69%) of 40 as a waxy 
yellow solid. 
1
H NMR (500 MHz, CDCl3)  7.88 (d, J = 8.79 Hz, 1H), 7.44 (d, J = 2.36 Hz, 1H), 7.17 - 7.29 
(m, 5H), 6.94 - 7.01 (m, 2H), 6.77 - 6.85 (m, 2H), 3.88 (s, 3H), 3.80 (s, 3H) 
13
C NMR (126 MHz, CDCl3)  159.8, 159.4, 147.5, 142.8, 142.5, 138.2, 132.1, 131.5, 131.0, 
126.9, 126.2, 123.7, 119.0, 117.5, 115.8, 114.7, 114.2, 55.5, 55.5 
4-bromo-2-iodothioanisole (41) 
4-bromo-2-iodoaniline (4.732g, 15.88 mmol) was dissolved in 40 mL acetonitrile in a three-neck 
round-bottomed flask with a stopper, condenser and septum. Methyl disulfide (1.464 g, 15.54 
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mmol, 0.979 eq.) was added dropwise to the dark purple solution. The reaction mixture was 
heated to 35° C, at which time isoamylnitrite (2.0 mL, 1.961 g, 17.73 mmol, 1.05 eq.) was added 
dropwise. The reaction mixture was stirred at the same temperature for 10 minutes; the oil bath 
temperature was then increased to 80°C. During this time a yellow precipitate formed with 
simultaneous gas evolution. After 30 to 60 minutes, production of yellow precipitation and gas 
evolution ceased. The reaction mixture was transferred to a round bottom flask and concentrated 
by rotary evaporation. The crude residue was purified by silica gel chromatography (5% EtOAc 
in hexanes), yielding 2.204g (42%) of a red oil. 
1
H NMR (500 MHz, CDCl3)  7.91 (d, J = 1.93 Hz, 1H), 7.45 (dd, J = 2.04, 8.47 Hz, 1H), 6.94 
(d, J = 8.58 Hz, 1H), 2.45 (s, 3H) 
13
C NMR (126 MHz, CDCl3)  142.8, 141.2, 131.9, 125.7, 118.3, 97.7, 17.4 
HRMS (EI): calc’d for C7H6BrIS (M
+
): 327.84185; found: 327.84125 
4-bromo-2-(4-methoxyphenylethynyl)thioanisole (42) 
4-bromo-2-iodothioanisole (2.196 g, 6.67 mmol), 4-ethynylanisole (950 mg, 7.168 mmol, 1.08 
eq.), CuI (78 mg, 0.409 mmol, 0.06 eq.) and PdCl2(PPh3)2 were combined in a round bottom 
flask. The flask was evacuated and backfilled three times with argon. Distilled Et3N (13 mL) was 
added, and the reaction mixture heated to 50°C for 6 hours. The reaction was cooled to room 
temperature, diluted with 50 mL saturated aqueous NH4Cl, then extracted 4 times with 50 mL 
ethyl acetate. The combined organic fractions were dried over MgSO4 and concentrated by rotary 
evaporation. The crude brown oil was purified by silica gel chromatography (9:1 hexanes : 
EtOAc) to yield 1.223g (55%) of a yellow oil which solidified upon standing. 
1
H NMR (500 MHz, CDCl3)  7.59 (d, J = 2.14 Hz, 1H), 7.48 - 7.53 (m, 2H), 7.38 (dd, J = 2.25, 
8.47 Hz, 1H), 7.00 (d, J = 8.58 Hz, 1H), 6.85 - 6.91 (m, 2H), 3.83 (s, 3H), 2.48 (s, 3H) 
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13
C NMR (126 MHz, CDCl3)  160.3, 140.9, 134.5, 133.4, 131.5, 125.7, 123.6, 117.6, 115.0, 
114.3, 97.5, 84.6, 55.6, 15.4 
HRMS (ESI): calc’d for C16H14BrOS (M+H)
+ 
: 332.9949; found: 332.9956 
5-bromo-3-iodo-2-(4-methoxyphenyl)benzo[b]thiophene (43) 
42 (1.174 g, 3.52 mmol) was dissolved in 35 mL CH2Cl2 at room temperature. Iodine (980 mg, 
3.86 mmol, 1.1 eq.) was added portionwise. The reaction was allowed to stir for 30 minutes; at 
this time 100 mL saturated Na2S2O3 were added, and the aqueous layer extracted 3 times with 50 
mL ethyl acetate. The combined organic extracts were dried over MgSO4 and concentrated by 
rotary evaporation to yield 1.450g (97%) of a pale yellow solid, which was used without further 
purification.  
1
H NMR (500 MHz, CDCl3)  7.96 (d, J = 1.72 Hz, 1H), 7.59 - 7.64 (m, 3H), 7.46 (dd, J = 1.93, 
8.36 Hz, 1H), 6.98 - 7.05 (m, 2H), 3.88 (s, 3H) 
13
C NMR (126 MHz, CDCl3)  160.5, 144.2, 143.9, 137.7, 131.5, 129.1, 128.6, 126.6, 123.6, 
119.7, 114.2, 55.6 
5-bromo-2,3-bis(4-methoxyphenyl)benzo[b]thiophene (44) 
Iodobromothiophene (1.287 g, 2.89 mmol), 4-methoxyphenylboronic acid (465 mg, 3.06 mmol, 
1.06 eq.), cesium carbonate (2.728 g, 8.37 mmol, 2.89 eq.) and PdCl2(dppf)(CH2Cl2) were 
combined in a three neck flask fitted with a glass topper, condenser and septum. The flask was 
evacuated and backfilled three times with argon. Under argon, 5.8 mL dioxane was added, and 
the flask was placed in a 100°C bath for 1 hour. After cooling to room temperature the reaction 
mixture was diluted with 25 mL brine and extracted 4 times with 25 mL ethyl acetate. The 
combined organic extracts were dried over MgSO4, and concentrated by rotary evaporation. The 
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crude residue was purified by silica chromatography (9:1 hexanes:EtOAc) to yield 718 mg 
(58%) of a white solid. 
1
H NMR (500 MHz, CDCl3)  7.69 (d, J = 8.58 Hz, 1H), 7.67 (d, J = 1.93 Hz, 1H), 7.39 - 7.44 
(m, 1H), 7.19 - 7.27 (m, 4H), 6.93 - 6.99 (m, 2H), 6.77 - 6.82 (m, 2H), 3.87 (s, 3H), 3.79 (s, 3H) 
13
C NMR (126 MHz, CHLOROFORM-d)  159.7, 159.3, 143.2, 141.2, 137.3, 131.7, 130.9, 
127.4, 126.6, 126.0, 123.5, 118.8, 114.6, 114.2, 55.5, 55.5 
HR-MS (ESI): calculated for C22H18O2BrS (M+H)
+
: 425.0211; found 425.0215 
General procedure M 
Pd(OAc)2 and BINAP were combined in a pressure tube with 1 mL toluene. The tube was fitted 
with a septum, evacuated and backfilled with argon (this cycle was repeated two more times). 
The tube was heated to 60°C for 30 minutes. The resulting homogeneous orange solution was 
cooled to room temperature. Benzothiophene bromide (1.0 eq.), aniline (1.5 eq.) and NaOtBu 
(1.5 eq.) were added, and the tube was closed with a Teflon screw cap. The tube was heated to 
150°C for 24 hours. After cooling to room temperature, the toluene solution was directly applied 
to a silica gel column and eluted with 5:1 hexanes : ethyl acetate, yielding the diarylamine 
product. 
N-(phenyl)-5-amino-2,3-bis(4-methoxyphenyl)benzo[b]thiophene (45a) 
Following general procedure M, the product was obtained as a white solid in 24% yield. 
1
H NMR (500 MHz, CDCl3)  7.73 (d, J = 8.58 Hz, 1H), 7.20 - 7.29 (m, 7H), 7.18 (dd, J = 2.25, 
8.47 Hz, 1H), 7.00 (d, J = 7.50 Hz, 2H), 6.91 - 6.95 (m, 2H), 6.88 (t, J = 7.40 Hz, 1H), 6.77 - 
6.83 (m, 2H), 5.72 (s, 1H), 3.84 (s, 3H), 3.78 - 3.81 (m, 3H) 
13
C NMR (126 MHz, CDCl3)  159.4, 159.0, 144.4, 142.7, 140.4, 140.1, 132.2, 131.8, 131.7, 
130.9, 129.6, 128.1, 127.1, 122.9, 120.5, 118.0, 116.7, 114.4, 114.0, 113.2, 55.5 
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HR-MS (ESI): Calculated for C28H24NO2S (M+H)
+
: 438.1528; found: 438.1530 
N-(4-fluorophenyl)-5-amino-2,3-bis(4-methoxyphenyl)benzo[b]thiophene (45b) 
Following general procedure M, the product was obtained as an orange solid in 24% yield. 
1
H NMR (500 MHz, CDCl3)  7.71 (d, J = 8.58 Hz, 1H), 7.21 - 7.27 (m, 4H), 7.17 (d, J = 1.72 
Hz, 1H), 7.09 (dd, J = 2.14, 8.58 Hz, 1H), 6.88 - 7.00 (m, 6H), 6.76 - 6.82 (m, 2H), 5.59 (s, 1H), 
3.84 (s, 3H), 3.79 (s, 3H) 
13
C NMR (126 MHz, CDCl3)  ppm 159.4, 159.0, 156.9, 142.7, 140.9, 140.5, 140.3 (d, J=2.8 
Hz), 131.8, 131.7, 131.7, 130.9, 128.1, 127.1, 122.9, 119.1 (d, J=7.4 Hz), 117.1, 116.1 (d, J=23.0 
Hz), 114.2, 112.0, 55.5 
HR-MS (ESI): calculated for C28H23FNO2S (M+H)
+
: 456.1434; found: 456.1432 
N-(3-fluorophenyl)-5-amino-2,3-bis(4-methoxyphenyl)benzo[b]thiophene (45c) 
Following general procedure M, the product was obtained as an orange solid in 31% yield. 
1
H NMR (500 MHz, CDCl3)  7.76 (d, J = 8.58 Hz, 1H), 7.21 - 7.29 (m, 5H), 7.10 - 7.21 (m, 
2H), 6.90 - 6.99 (m, 2H), 6.76 - 6.83 (m, 2H), 6.64 - 6.73 (m, 2H), 6.53 (m, 1H), 5.79 (s, 1H), 
3.85 (s, 3H), 3.79 (s, 3H) 
13
C NMR (126 MHz, CDCl3)  ppm 159.4, 159.0, 156.9, 142.7, 140.9, 140.5 (s), 140.3, 131.8, 
131.7, 131.7, 130.9, 128.1, 127.1, 122.9, 119.1 (d, J=7.4 Hz), 117.1, 116.1 (d, J=22.1 Hz), 114.4, 
114.0, 112.0, 55.5 
HR-MS (ESI): calculated for C28H23FNO2S (M+H)
+
: 456.1434; found: 456.1436 
General procedure I 
Benzo[b]thiophene dimethyl ethers were dissolved in dichloromethane and cooled to 0°C. BBr3 
(1.0M in dichloromethane, 5.0 eq.) was added to the reaction. The reaction was stored at -20°C 
overnight, and then warmed to 0°C. Cold methanol was slowly added to quench the reaction. 
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The solvents were removed by rotary evaporation. The residue was dissolved in a small amount 
of ethyl acetate and purified by preparative TLC. 
N-(phenyl)-5-amino-2,3-bis(4-hydroxyphenyl)benzo[b]thiophene (46a) 
Following general procedure I, the product was isolated as a white solid in 80% yield. 
1
H NMR (500 MHz, acetone-d6)  8.64 (s, 1H), 8.54 (s, 1H), 7.78 (d, J = 8.58 Hz, 1H), 7.29 (d, J 
= 2.14 Hz, 1H), 7.08 - 7.25 (m, 9H), 6.87 - 6.94 (m, 2H), 6.75 - 6.84 (m, 3H) 
13
C NMR (126 MHz, acetone-d6)  163.6, 157.0, 142.8, 141.2, 140.0, 131.6, 130.8, 129.3, 126.9, 
126.0, 122.7, 121.7, 119.9, 117.2, 116.7, 115.8, 115.7, 115.5, 115.4, 111.2 
HR-MS (ESI): calculated for C26H20NO2S (M+H)
+
: 410.1215; found: 410.1216 
N-(4-fluorophenyl)-5-amino-2,3-bis(4-hydroxyphenyl)benzo[b]thiophene (46b) 
Following general procedure I, the product was isolated as a purple solid in 42% yield. 
1
H NMR (500 MHz, acetone-d6)  8.57 (s, 1H), 8.48 (s, 1H), 7.77 (d, J = 8.58 Hz, 1H), 7.41 (s, 
1H), 7.07 - 7.27 (m, 8H), 6.96 - 7.05 (m, 2H), 6.85 - 6.94 (m, 2H), 6.71 - 6.81 (m, 2H) 
13
C NMR (126 MHz, CD3OD)  ppm 157.2 - 157.3 (m), 156.7 - 156.7 (m), 142.6 (s), 140.2 (s), 
140.0 (s), 131.7 (s), 131.4 (s), 130.5 (s), 130.2 (s), 130.1 (s), 126.9 (s), 125.9 (s), 122.3 (s), 117.5 
(s), 115.4 (s), 115.0 (s), 112.2 (s), 111.3 (s), 105.1 (d, J=21.2 Hz) 
HR-MS (ESI): calculated for C26H19NO2FS (M+H)
+
: 428.1121; found: 428.1117 
N-(3-fluorophenyl)-5-amino-2,3-bis(4-hydroxpyhenyl)benzo[b]thiophene (46c) 
Following general procedure I, the product was isolated as a silver solid in 61% yield. 
1
H NMR (500 MHz, CD3OD)  7.71 (dd, J = 0.43, 8.58 Hz, 1H), 7.25 (dd, J = 0.54, 2.25 Hz, 
1H), 7.06 - 7.18 (m, 6H), 6.80 - 6.86 (m, 2H), 6.78 (m, 1H), 6.71 (dd, J = 2.25, 11.68 Hz, 1H), 
6.64 - 6.68 (m, 2H), 6.42 - 6.47 (m, 1H) 
HR-MS (ESI): calculated for C26H19NO2FS (M+H)
+
: 428.1121; found: 428.1125 
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Chapter 3: Inhibition of the Estrogen Receptor/Coactivator Protein Interaction 
3.1 INTRODUCTION 
 One recent trend in breast cancer therapy involves inhibition of the ER/coactivator 
binding protein interaction. This approach may succeed in cases of SERM resistance. Tamoxifen 
resistance, in some cases, occurs when the ER undergoes post-translational modifications that 
render it active even in the absence of ligand. This form of ER still requires coactivator proteins 
for its transactivation function. Thus, inhibiting the ER/coactivator interaction would still inhibit 
ER function. 
3.2 PEPTIDOMIMETICS 
 As mentioned in Chapter 1, the ER binds to many different types of steroid receptor 
coactivator (SRC) proteins containing LXXLL sequences which interact with a groove on the 
surface of the ER (Figure 3.1). Traditionally, inhibition of protein-protein interactions with a 
small molecule is considered to be difficult. First, the surface areas being targeted are typically 
larger than a typical binding pocket in a receptor protein. Second, the surfaces of proteins are 
flexible, resulting in a lack of a well-defined interaction surface. In the case of coactivator 
proteins, their widespread use by many different transcription factors makes selectivity an issue. 
 Despite these potential drawbacks, the development of effective inhibitors of protein-
protein interactions represents a promising goal in medicinal chemistry. These inhibitors can be 
small molecules or modified peptides. Peptidomimetics refers to the use of small molecules 
which mimic key structural features of one of the proteins being involved in the interaction. 
Peptidomimetic compounds have been designed to mimic various secondary structures, 
including α-helices and β-sheets. 
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 The α-helix motif plays a key role in many important protein-protein interactions, 
including p53/MDM2, Bcl-xL/Bak, and nuclear receptor / coactivator protein interactions.
1
 These 
helices typically contain hydrophobic residues along one face of the helix positions i, i + 3 or 4, 
and i + 7. Several different peptidomimetic cores have been designed for disrupting protein-
protein interactions such as the ones mentioned above (Figure 3.2). Hamilton designed a 
terphenyl system with pendant alkyl chains to mimic these interactions. Terphenyl 1 inhibited the 
Bcl-xL / Bak interaction with a Ki of 0.112 µM, mimicking the VXXLXXI motif found in Bak; 
any other pattern of alkyl substitution lowered the activity 10-fold.
2
 Compound 1 also inhibited 
the p53/DM2 interaction with a Ki of 0.182 µM.
3
 The p53 protein contains an FXXWXXL α-
helix similar to the one found in the Bcl-xL/Bak interaction. The ability of one compound to 
inhibit two different protein-protein interactions at different affinities could prove to be a 
problem. These initial compounds showed good binding affinity; however, they were unlikely to 
be good pharmaceutical candidates as they are very nonpolar. Hamilton developed a second 
generation of more polar scaffolds. Terephthalamide 2 inhibited the Bcl-xL/Bak interaction with 
a Ki of 0.78 µM.
4
 These terephthalamides were not tested with other protein-protein interactions. 
High throughput screening led to the identification of  several imidazolines as potential 
inhibitors of p53/MDM2 interaction.
5
 Cis-imidazoline 3, also known as Nutlin-1, bound with an 
IC50 of 0.26 µM. In 2010, inhibitors of the activity of importin α/β were identified in a screening 
process.
6
 The best of these, 4, exhibited an IC50 of 106 µM.   
All of the inhibitors described above mimic three turns of an α-helix, while the target 
sequence in the ER/SRC interaction is a shorter two-turn α-helix. Some inhibitors of the ER/SRC 
interaction are known in the literature (Figure 3.3). Lead guanylhydrazone 5 was identified by 
Wyeth in a high throughput screen;
7
 analogs of this compound were prepared by LaFrate et al., 
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with some showing improved activity.
8
  The Katzenellenbogen group investigated an “outside-
in” approach in which isobutyl chains mimicking leucine residues were placed around varying 
cyclic and heterocyclic cores.
9
 The trisubstituted pyrimidine core proved to be successful; further 
development of 6 led to several compounds with micromolar Ki and IC50 values.
10
 This approach 
has also been extended to the androgen receptor (AR) / coactivator interaction.
11
 The AR 
interacts with coactivators in which the leucines are replaced by phenylalanines or tryptophans; 
using substituents larger than isobutyl resulted in compounds selective for the AR over the ER. 
Hamilton created CBIs using biaryl compounds such as 7.
12
 These compounds had low 
micromolar Ki values; one of these compounds was picked and shown to have very low affinity 
for the ER. Williams et al. attempted to make CBIs based on a biphenyl scaffold containing 
hydrogen bonding groups at the ends to interact with the charge clamp found in the coactivator 
binding groove.
13
 Even the best compound of these, compound 8, bound with poor potency and 
exhibited low efficacy. There is still a need for high-affinity ER CBIs. 
3.3 DESIGN AND SYNTHESIS 
Following Hamilton’s peptidomimetic scaffold, previous workers in the 
Katzenellenbogen group designed terphenyl CBIs to mimic a two-turn α-helix (Figure 3.4), 
instead of the three-turn α-helix mimicked by Hamilton’s design. These compounds proved 
difficult to make, due to the o,o’-dialkylbiphenyl moiety contained within the target scaffold. 
3.3.1 Diarylfurans 
Following Hamilton’s strategy of using heterocycles to make the core more “drug-like”, 
we modified the original terphenyl design by replacing the middle ring with heterocycles that 
could be made by condensation reactions (Figure 3.5). The formation of these aromatic rings 
could provide a driving force to overcome the steric hindrance of the o,o’-dialky groups. We 
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proposed using an ether linkage for the alkyl group to allow for facile alkylation of the aromatic 
rings. The Katzenellenbogen group has synthesized several di-substituted and tri-substituted 
heterocycles from a common 1,4-diketone precursor.
14
 One successful method previously 
employed involved the reaction of aldehydes and enones using Stetter chemistry. While this 
reaction worked well for the para substituted chalcone, it did not produce the 1,4-diketone when 
the ortho substituted chalcone was used (Scheme 3.1).  
Similar 1,4-diketones have been synthesized by oxidative coupling of enolates.
11
 We 
were able to couple 2’-methoxyacetophenone using CuCl2 to generate diketone 11 in low yields 
(Scheme 3.2). This compound could be effectively cyclized via a Paal-Knorr reaction to furan 
12a using TsOH, or to pyrrole 12b using ammonium bicarbonate as an ammonia source. 
Looking for a higher yielding diketone synthesis, we attempted homocoupling of 2’-
methoxyacetophenone with 0.5 equivalents of I2 (Scheme 3.3). This approach generates 0.5 
equivalents of α-iodo enone and 0.5 equivalents of the enolate of the starting ketone. This enolate 
typically undergoes an SN2 reaction with the α-halo ketone to generate the desired symmetrical 
1,4-diketone. Repeated attempts to synthesize diketone 11 by this method were unsuccessful. 
1
H 
NMR analysis indicated that the product was not symmetrical, and the mass spectrum of the 
product indicated a loss of water. These two observations indicated that a coupling had taken 
place, followed by a dehydration that did not form 11. These data are consistent with 13 as the 
product. This type of furan synthesis is known as a Feist-Benary furan synthesis, in which a 
ketone or ester and α-halo ketone or α-halo ester couple to produce a furan.15 The likely 
mechanism (Scheme 3.4) generates the same intermediates as anticipated. Instead of the enolate 
alkylating at the α-carbon, however, it undergoes an aldol condensation followed by closure to 
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the epoxide in a manner analogous to the beginning of the Darzens condensation. Intramolecular 
opening of the epoxide followed by dehydration would produce the observed product. 
Having demonstrated that diarylfurans could be prepared via a Feist-Benary furan 
synthesis, we moved forward towards the synthesis of an alkylated diarylfuran (Scheme 3.5). 2’-
hydroxyacetophenone was alkylated with isobutyl bromide or isopentyl bromide in DMF to 
produce 14a-b. These products were treated with LDA, followed by quenching with iodine at -78 
°C. The diarylfuran products 15a-b were isolated in low yield. 
These furans only had substituents mimicking the i and i + 4 residues, so we attempted to 
incorporate an alkyl chain into the furan ring. We chose to replace the ketone with a β-keto ester; 
this component would be more reactive, and could later be transformed into an alkyl group. In a 
model system, 2’-methoxyacetophenone was acylated with diethyl carbonate in 66% yield 
(Scheme 3.6). β-Keto esters have been used in an interrupted Feist-Benary synthesis developed 
by Calter which uses the much milder triethylamine as a base and a preformed phenacyl 
bromide.
16
 Treatment of β-keto ester 16 with 2-bromo-2’-methoxyacetophenone did not yield the 
Feist-Benary product 17. 
3.3.2 Diaryloxazoles 
We then turned towards the synthesis of oxazoles as an alternatve to the central furan 
ring. We briefly explored direct coupling and condensation between phenacyl bromides and 
benzamides, but these reactions did not reliably produce product. The Gabriel oxazole synthesis 
was then explored, in which an acyl α-amino ketone is cyclized under acidic conditions similar 
to the Paal-Knorr synthesis used to prepare furan 12a and pyrrole 12b. 
2’-Methoxyacetophenone was brominated with Br2 in ether to generate the α-bromo 
ketone (Scheme 2.7). The bromide was then displaced with sodium azide, yielding α-azido 
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ketone 18 in high yield. Initial attempts to hydrogenate the azide did not produce the α-amino 
ketone. Staudinger reduction with triphenylphosphine led to pyrazine 20; this reaction likely 
proceeded through an aza-Wittig mechanism (Scheme 2.7). We then retried the azide 
hydrogenation with the addition of drops of concentrated HCl. This allowed α-amino ketone 19 
to be isolated as an HCl salt. This amine was acylated with acid chloride to generate the acyl α-
amino ketone 21. Dehydration with TsOH did not induce cyclization. Nicolaou developed mild 
conditions (POCl3/pyridine) to dehydrate acyl α-amino ketones to form oxazoles; these 
conditions were effectively used in the total synthesis of diazonamide A. These conditions were 
effectively used in our hands to convert 21 to oxazole 22. 
Having generated a model oxazole, we then turned towards synthesizing the target 
oxazoles. We wanted to incorporate an alkyl chain on the internal oxazole, which would require 
generating branched α-amino ketones. Synthesizing the alkyl aryl ketones proved to be difficult. 
We then redesigned the diaryloxazole synthesis to use naturally occurring amino acids as the 
precursor to the amino ketones.  
We designed a model system for a new route to diaryloxazoles beginning with amino 
acids. We proposed that the aminoketones could be synthesized by addition of an organometallic 
reagent to Weinreb amides derived from amino acids. This route has previously been employed 
to synthesize oxazoles.
17
 Screening of a variety of conditions for preparation of the Weinreb 
amide led to a high-yielding synthesis which did not require purification of the product (Scheme 
3.8). Coupling of Weinreb amine with Boc-protected amino acids using EDCI/HOBt in DMF 
with ethyldiisopropylamine as the base produced Weinreb amide 23 in high yield without 
requiring further purification. In the next step we attempted adding Grignard and organolithium 
reagents to the Weinreb amide to generate the α-amino ketone.18 Compound 24 was synthesized 
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by first deprotonating with a sacrificial equivalent of isopropylmagnesium chloride, followed by 
addition of phenylmagnesium chloride. To test whether this approach would work for more 
functionalized Grignards, 27a was converted to the corresponding Grignard reagent, then added 
to Boc-Ala Weinreb amide to yield 25. This approach suffers from the requirement that excess 
Grignard reagent is used to deprotonate the carbamate before addition to the Weinreb amide. We 
utilized a one-pot methodology developed by Merck in which a mixture of an aryl iodide (27) 
and Weinreb amide was treated with isopropylmagnesium chloride.
19
 The first equivalent of 
Grignard reagent removed the carbamate proton. The second equivalent could either react with 
the Weinreb amide, resulting in an isopropyl alkyl ketone, or undergo an iodine-magnesium 
exchange. Fortunately for us, at low temperatures (< -50°C) the iodine-magnesium exchange 
proved to be faster than Grignard reaction with the Weinreb amide. The resulting Grignard 
reagent successfully reacted with the Weinreb amide to generate the desired α-amino ketone 26. 
This approach did not work using nBuLi. 
The general methodology used to generate 26 was applied to the synthesis of substituted 
oxazoles (Scheme 3.9). The Boc group was readily removed using a solution of HCl in either 
dioxane or ether, allowing isolation of the hydrochloride salt 28. Compound 28b was carried on 
to test the final steps of the synthesis, as the oxazole derived from this product would likely be 
the best oxazole CBI. Coupling of this hydrochloride salt with 32 yielded acyl α-aminoketone 
29. Cyclization using the POCl3 / pyridine system previously described successfully produced 
oxazole 30. 
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3.4 ANALYSIS 
Coactivator Binding Inhibition 
 Furans 15 and diaryloxazole 31 were tested in a FRET-based assay measuring coactivator 
binding inhibition. Unfortunately, none of the synthesized compounds displayed any disruption 
of the ER/SRC interaction. The lack of activity shown by oxazole 31 suggests a flaw in the 
diaryloxazole design. Taking a closer look at the superposition of our model teraryl design with a 
coactivator peptide led us to realize our original design did not follow Hamilton’s design as 
closely as we had first thought.   
Redesign of Ligands 
 Jacoby published a scaffold specifically designed to mimic the i, i + 1, i + 3, and i + 4 
residues of an α-helix;20 this design would mimic the SRC peptide better than Hamilton’s design 
which targets a larger α-helix. This scaffold contains a sterically hindered di-ortho substituted 
biaryl. Recent developments in transition metal-catalyzed cross-coupling reactions have allowed 
for synthesis of sterically hindered biaryls. Like the original Hamilton terphenyls, these 
compounds would likely be too nonpolar to be an effective drug. One or both of the phenyl rings 
could be replaced with heterocycles to create compounds like Hamilton’s biaryl CBIs. 
3.5 CONCLUSIONS 
 We designed and synthesized potential inhibitors of the ER – SRC interaction. These 
compounds were proposed to effectively inhibit proliferation in ER-positive cancer cells, even in 
cases where these cancers have developed resistance to SERM treatment. Our peptidomimetic 
design did not produce effective CBIs. With a more carefully designed scaffold the ER – SRC 
interaction might be more effectively inhibited by peptidomimetic small molecules. 
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3.6 FIGURES 
 
 
Figure 3.1 Representation of the coactivator binding groove. The electrostatic potential of the receptor is shown, with 
hydrophobic regions shown in brown and hydrophilic regions shown in blue. The key leucine side chains are shown, which bury 
themselves into the hydrophobic regions. At the top and the bottom of the groove are the hydrogen bonding charge clamp 
residues. 
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Figure 3.2 Previous inhibitors of protein-protein interactions based on α-helix mimicry. 
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Figure 3.3 Inhibitors of the ER/SRC interaction reported in the literature. 
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Figure 3.4 (A) The terphenyl scaffold designed by Hamilton to mimic a three-turn α-helix. The alkyl group on the central ring is 
reported to mimic either the i + 3 or the i + 4 residue. (B) Modification of the previous terphenyl scaffold to mimic a two-turn α-
helix. (C) Second generation of the terphenyl scaffold in 4B. 
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Figure 3.5  The scaffolds from 4A and 4B (blue) are overlayed with a fragment from the coactivator peptide GRIP-1 (green). 
Only the hydrophobic  sidechains are shown for clarity. 
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Scheme 3.1 Attempted Stetter synthesis of 1,4-diketones. 
 
Scheme 3.2 Paal-Knorr synthesis of 2,5-diarylfuran and 2,5-diarylpyrrole. 
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Scheme 3.3 Unexpected synthesis of 2,4-diarylfurans. 
 
Scheme 3.4 Mechanism of Feist-Benary reaction. 
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Scheme 3.5 Synthesis of 2,4-bis(2-alkoxyaryl)furans via Feist-Benary synthesis. 
 
Scheme 3.6 Second attempt at Feist-Benary furan synthesis using a β-keto ester as nucleophile, 
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Scheme 3.7 Synthesis of α-aminoketones via reduction of azides. 
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Scheme 3.8 Development of Weinreb amide route to diaryloxazoles. 
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Scheme 3.9 Synthesis of diaryloxazole using Weinreb amide route. 
 
 
3.7 EXPERIMENTAL 
All reagents used were purchased from Aldrich Chemical Company, Fisher Scientific, or TCI 
America and used without further purification unless otherwise specified. Anhydrous THF, ether, 
dichloromethane, toluene, dioxane, DMF, DMSO, and acetonitrile were obtained from a solvent 
delivery system. Anhydrous triethylamine, diisopropylethylamine, and diisopropylamine were 
obtained by distillation from calcium hydride. When necessary, organolithium and 
organomagnesium reagents were titrated with menthol / 1,10-phenanthroline. Reaction progress 
was monitored by thin-layer chromatography (TLC) using glass-backed silica gel plates with 
fluorescent indicator. Unless otherwise specified, reaction temperatures refer to external bath 
temperatures. Flash chromatography was performed using 40-63 µm particle size (230 – 400 
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mesh) silica gel from Silicycle. 
1
H and 
13
C NMR spectra were obtained on Varian 400 or 500 
MHz FT-NMR instruments. Chemical shifts (δ) are reported in parts per million and are 
referenced to residual undeuterated solvent peaks. Mass spectra were obtained on a Micromass 
Quattro or Micromass Q-Tof mass spectrometer. Melting points were obtained on a Thomas-
Hoover apparatus and are uncorrected. 
(E)-1,3-bis(2-methoxyphenyl)prop-2-en-1-one (9) 
2’-methoxyacetophenone (1.08g, 7.2 mmol) and o-anisaldehyde (1.08g, 7.92 mmol, 1.1 eq.) 
dissolved in 5 mL ethanol and 5 mL water. KOH (317g, 7.92 mmol, 1.1 eq.) was added, and the 
reaction stirred at room temperature for 1 hour. The ethanol was removed by rotary evaporation, 
and the crude residue exhaustively extracted with ethyl acetate. The combined organic extracts 
were washed with brine, dried over MgSO4 and concentrated to afford to yield a yellow oil, 
which was used without further purification. 
1
H NMR (499 MHz, CDCl3)  7.95 (d, J = 16.11 Hz, 1H), 7.56 - 7.63 (m, 2H), 7.44 - 7.48 (m, 
1H), 7.42 (d, J = 16.11 Hz, 1H), 7.32 - 7.38 (m, 2H), 6.94 - 7.06 (m, 5H), 3.89 (s, 3H), 3.87 (s, 
3H) 
1,4-bis(2-methoxyphenyl)-1,4-butanedione (11) 
LDA (1.8M in heptanes/THF/ethylbenzene, 6.5 mL, 11.7 mmol) was added to 4 mL of dry THF 
and cooled to -78°.  2’-methoxyacetophenone (1.252g, 9 mmol) dissolved in 12 mL of THF was 
added dropwise. The solution stirred at this temperature for 30 minutes before a solution of 
CuCl2 (1.344g, 10 mmol) in 15 mL of dry DMF was added. The reaction stirred at this 
temperature for 1 hour, before being allowed to warm to room temperature. The reaction mixture 
was diluted with brine and extracted several times with ethyl acetate. The combined organic 
extracts were washed with brine, dried over MgSO4, and concentrated. The crude residue was 
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purified by column chromatography (4:1 hexanes:EtOAc) to yield 402 mg (30%) of the product 
as a tan powder.  
1
H NMR (499 MHz, CDCl3)  7.75 (dd, J = 1.83, 7.69 Hz, 2H), 7.41 - 7.50 (m, 2H), 6.93 - 7.04 
(m, 4H), 3.91 (s, 6H), 3.41 (s, 4H) 
2,5-bis(2-methoxyphenylfuran (12a) 
Diketone 11 (600 mg, 2 mmol) and a few crystals of p-toluenesulfonic acid monohydrate were 
dissolved in 25 mL of toluene. The reaction flask was fitted with a Dean-Stark trap and heated at 
reflux for four hours. After cooling to room temperature a brown precipitate formed. This 
product was filtered and dried, yielding 492 mg (86%) of product. 
1
H NMR (499 MHz, CDCl3)  8.00 (m, 2H), 7.22 - 7.25 (m, 2H), 7.02 - 7.09 (m, 4H), 6.97 (d, J 
= 8.30 Hz, 2H), 3.97 (s, 6H) 
13
C NMR (126 MHz, CDCl3)  205.3, 155.7, 128.0, 126.1, 121.0, 112.6, 111.2, 55.6 
HR-MS (ESI): calculated for C18H17O3 (M+H)
+
: 281.1178; found: 281.1167 
2,5-bis(2-methoxyphenyl)pyrrole (12b) 
Diketone 11 and ammonium formate were combined with acetic acid and heated to 100°C for 5 
hours. After cooling to room temperature most of the acetic acid was removed by rotary 
evaporation. The remaining acid was quenched with saturated ammonium carbonate. The 
resulting solution was extracted exhaustively with ethyl acetate. The combined organic extracts 
were washed with brine and dried over Na2SO4. The crude product was purified by column 
chromatography (3:1 hexanes:EtOAc) to yield 258 mg (58%) yield of a purple foam. 
1
H NMR (400 MHz, CDCl3)  7.64 - 7.73 (m, 2H), 7.10 - 7.20 (m, 2H), 6.94 - 7.04 (m, 5H), 6.68 
(d, J = 2.69 Hz, 2H), 4.02 (s, 6H) 
HR-MS (ESI) calculated for C18H18NO2: 280.1338; found: 280.1322 
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2,4-bis(2-methoxyphenyl)furan (13) 
LDA (1.8M in heptanes/THF/ethylbenzene, 6.7 mL, 12 mmol) was added to 20 mL dry THF and 
cooled to -78°C. 2’-methoxyacetophenone (1.09g, 10 mmol) was added as a solution in THF. 
The resulting solution was stirred at this temperature for 30 minutes before a solution of I2 (0.5 
eq.) in THF was added. The reaction was allowed to warm to room temperature over 3 hours. 
The THF was removed by rotary evaporation. The residue was dissolved in 100 of mL EtOAc 
and washed with 20 of mL 10% Na2S2O3, 20 mL of water, 0.5 M HCl, and 20 mL of brine. The 
organic layer was dried over MgSO4 and concentrated. The crude residue was purified by flash 
chromatography (3:1 hexanes:EtOAc) to yield 624 mg (45%) of a white powder. 
1
H NMR (499 MHz, CDCl3)  8.05 (d, J = 0.98 Hz, 1H), 7.90 (dd, J = 1.83, 7.69 Hz, 1H), 7.63 
(dd, J = 1.71, 7.57 Hz, 1H), 7.35 (d, J = 0.73 Hz, 1H), 7.23 - 7.29 (m, 2H), 7.01 - 7.07 (m, J = 
1.00, 5.30, 7.50, 7.50 Hz, 2H), 6.96 - 7.01 (m, J = 1.00, 3.20, 8.20 Hz, 2H), 3.99 (s, 3H), 3.95 (s, 
3H) 
13
C NMR (126 MHz, CDCl3)  156.8, 155.6, 149.9, 140.7, 128.3, 128.2, 127.8, 126.2, 123.6, 
121.7, 121.0, 120.1, 111.2, 109.6, 55.7, 55.6 
HR-MS (ESI): calculated for C18H17O3 (M+H): 281.1178; found: 281.1162 
General procedure A 
2’-hydroxyacetophenone, alkyl bromide, and potassium carbonate were combined in a round 
bottomed flask with DMF. The reaction mixture was stirred at room temperature for 6 hours. 
Water and brine were added, followed by extraction several times with ethyl acetate. The 
combined organic layers were washed with water, brine, dried over MgSO4 and concentrated by 
rotary evaporation. The crude product contained some starting material, which was removed by 
dissolving in chloroform and washing with 1N NaOH, drying over MgSO4 and concentrating. 
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2’-(2-isobutoxyphenyl)acetophenone (14a) 
Following general procedure A, the product was obtained in 34% yield as a light yellow oil. 
1
H NMR (400 MHz, CDCl3)  7.72 (dd, J = 1.71, 7.81 Hz, 1H), 7.37 - 7.42 (m, 1H), 6.87 - 6.97 
(m, 2H), 3.79 (d, J = 6.35 Hz, 2H), 2.63 (s, 3H), 2.13 (d, J = 6.59 Hz, 1H), 1.04 (d, J = 6.59 Hz, 
6H) 
13
C NMR (101 MHz, CDCl3)  200.0, 158.8, 133.9, 130.6, 128.3, 120.5, 112.4, 75.2, 32.4, 28.5, 
19.7 
2’-(2-isopentoxyphenyl)acetophenone (14b) 
Following general procedure A, the product was obtained in 82% as a light yellow oil. 
1
H NMR (499 MHz, CDCl3)  7.73 (dd, J = 1.71, 7.57 Hz, 1H), 7.38 - 7.47 (m, 1H), 6.91 - 7.01 
(m, 2H), 2.62 (s, 3H), 1.85 (spt, J = 6.70 Hz, 1H), 0.98 (d, J = 6.59 Hz, 6H) 
13
C NMR (101 MHz, CDCl3)  200.1, 158.7, 133.6, 130.5, 128.4, 120.8, 112.4, 67.0, 38.2, 32.4, 
25.4, 22.5 
2,4-bis(2-isobutoxyphenyl)furan (15a) 
Using the procedure as described for 13, 110 mg (20%) of a white powder was obtained. 
1H NMR (500 MHz, CDCl3) δ: 8.12 (d, J = 0.7 Hz, 1H), 7.90 (dd, J1 = 1.7 Hz, J2 = 7.8 Hz, 1H),  
7.56 (dd, J1 = 1.7 Hz, J2 = 7.7 Hz, 1H),   7.43 (d, J = 0.8 Hz), 7.26 – 7.21 (m, 2H), 7.04 – 7.00 
(m, 2H),  6.97 (d, J = 8.1 Hz, 2H), 3.91 (d, J = 6.3 Hz), 3.86 (J = 6.4 Hz), 2.33 – 2.18 (m, 2H), 
1.15 (d, J = 6.5 Hz, 6H), 1.10 (d, J = 6.8 Hz, 6H) 
MS (CI): 364.2 
2,4-bis(2-isopentoxyphenyl)furan (15b) 
Using the procedure as described for 13, 294 mg (31%) of a white powder was obtained. 
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1
H NMR (500 MHz, CDCl3)  ppm 8.1 (d, J=0.9 Hz), 7.9 (dd, J=7.7, 1.7 Hz), 7.6 (dd, J=7.5, 1.7 
Hz), 7.4 (d, J=0.6 Hz), 7.2 - 7.3 (m), 7.0 - 7.0 (m), 7.0 (d, J=8.1 Hz), 4.2 (t, J=6.4 Hz), 4.1 (t, 
J=6.6 Hz), 2.0 (spt, J=6.6 Hz), 1.8 - 2.0 (m), 1.0 (d, J=6.6 Hz), 1.0 (d, J=6.4 Hz) 
13
C NMR (126 MHz, CDCl3)  155.1, 140.7, 129.1, 128.2, 127.8, 127.6, 126.0, 123.6, 121.7, 
120.7, 120.7, 111.9, 111.9, 109.6, 66.9, 66.8, 65.7, 57.7, 38.4, 38.4, 25.5, 22.9 
HR-MS (ESI): calculated for C26H33O3 (M+H)
+
: 393.2430; found: 393.2430  
Ethyl 3-(2-methoxyphenyl)-3-oxopropionate (16). 2’-Methoxyacetophenone (6mL, 6.52g, 43.4 
mmol) was dissolved in diethyl carbonate (50mL, 51.3g, 434 mmol) and 50 mL of dry THF in a 
200 mL round-bottomed flask. NaH (2.08g, 60% dispersion in mineral oil) was washed with 
THF, then added slowly to the reaction mixture. The flask was then placed in an oil bath and 
heated at 85ºC for 2 hours. The reaction turned bright yellow, and then began to turn yellow-
orange. After cooling to room temperature, the reaction mixture was slowly poured over an ice / 
acid mixture. Ethyl acetate was added to this solution, and the layers were separated. The ethyl 
acetate was washed with brine, dried over sodium sulfate, and concentrated to afford a yellow 
oil. The oil was purified by column chromatography (4:1 hexanes:ethyl acetate) to give 6.4g 
(66%) of β-keto ester. The NMR spectrum showed a 10:1 keto:enol ratio. NMR data is given for 
the keto form only. 
1
H NMR (500 MHz, CDCl3)  7.86 (dd, J = 1.82, 7.83 Hz, 1H), 7.45 - 7.51 (m, 1H), 6.97 - 7.03 
(m, 1H), 6.94 (dd, J = 0.64, 8.36 Hz, 1H), 4.16 (q, J = 7.07 Hz, 2H), 3.94 (s, 2H), 3.87 (s, 3H), 
1.21 (t, J = 7.07 Hz, 3H) 
13
C NMR (126 MHz, CDCl3)  193.3, 168.4, 159.4, 134.9, 131.3, 126.4, 121.0, 111.8, 61.1, 
55.5, 50.9, 14.3 
2-bromo-2’-methoxyacetophenone 
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2’-methoxyacetophenone (10.9g, 72.3 mmol) was dissolved in 250 mL dry ether in a round 
bottom flask with stirring. A small scoop of AlCl3 was added as a catalyst, which turned the 
color of the reaction pale yellow. Bromine (3.74 mL, 11.6g, 72.3, mmol) was added dropwise. 
During the course of the addition, the reaction transiently turned orange before fading. At the end 
of the addition the reaction maintained an orange color. After stirring for 30 minutes, the reaction 
was carefully poured into ice / NaHCO3 / water and stirred until colorless. The organic layers 
were separated, washed with brine, dried over Na2SO4, and concentrated to yield 14.36g (87%) 
of a clear oil which solidified upon storage at -20°C. The product was used without further 
purification. 
1
H NMR (400 MHz, CDCl3)  7.82 (dd, J = 2.20, 8.06 Hz, 1H), 7.48 - 7.55 (m, 1H), 6.96 - 7.06 
(m, 2H), 4.61 (s, 2H), 3.94 (s, 3H) 
13
C NMR (101 MHz, CDCl3)  193.5, 159.2, 135.0, 131.8, 125.0, 121.3, 111.8, 55.8, 38.1 
2-azido-2’-methoxyacetophenone (18) 
2-bromo-2’-methoxyacetophenone (1.000g, 4.365 mmol) was dissolved in 30 mL acetone. 
Sodium azide (426 mg, 6.55 mmol) added in one portion. The reaction mixture was refluxed for 
2 hours before cooling to room temperature. The solids were filtered off, and the acetone 
removed by rotary evaporation to yield 820 mg (100%) of product. 
1
H NMR (400 MHz, CDCl3)  7.93 (dd, J = 1.71, 7.81 Hz, 1H), 7.49 - 7.58 (m, 1H), 7.03 - 7.09 
(m, 1H), 6.96 - 7.02 (m, 1H), 4.52 (s, 2H), 3.94 (s, 3H) 
13
C NMR (126 MHz, CDCl3)  196.5, 139.7, 134.5, 132.8, 132.7, 128.6, 126.2, 56.7, 21.8 
2-amino-2’-methoxyacetophenone hydrochloride (19) 
150 mg 2-azido-2’-methoxyacetophenone was dissolved in MeOH in a glass bottle. 0.5 mL 
concentrated HCl and Pd/C (20 mg, 10% Pd/C) were added. The reaction vessel placed in a Parr 
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shaker and pressurized to 30 psi. After 4 hours, the reaction mixture was filtered through celite. 
The methanol was evaporated to yield 156 mg (99%) of a tan solid. 
1
H NMR (500 MHz, CD3OD)  7.98 (dd, J = 1.72, 7.93 Hz, 1H), 7.61 - 7.70 (m, 1H), 7.23 (d, J 
= 8.58 Hz, 1H), 7.10 (t, J = 7.50 Hz, 1H), 4.91 (br. s., 3H), 4.43 (s, 2H), 4.01 (s, 3H) 
13
C NMR (126 MHz, CD3OD)  191.7, 160.6, 136.3, 130.5, 123.1, 120.9, 112.3, 55.2, 49.2 
HR-MS (ESI) calculated for C9H12NO2 (M
+
): 166.0868; found: 166.0873 
2,5-bis(2-methoxyphenyl)pyrazine (20) 
2-azido-2’-methoxyacetophenone (400 mg, 2.09 mmol) was dissolved in 25 mL dry THF. 
Triphenyphosphine (823 mg, 3.14 mmol) was added portionwise, and the reaction mixture 
heated to reflux for 18 hours. The reaction was cooled to room temperature and the THF 
removed by rotary evaporation. Ether was added to the crude residue. After filtration of 
undissolved solids, the ether was washed with saturated NaHCO3, brine, dried over Na2SO4 and 
concentrated. The crude product was purified by column chromatography (3:1  1:2 
hexanes:EtOAc) to yield 77 mg 25% of 20 as a yellow powder. 
1
H NMR (499 MHz, CDCl3)  9.26 (s, 2H), 7.94 (dd, J = 1.59, 7.69 Hz, 2H), 7.37 - 7.49 (m, 
2H), 7.14 (dt, J = 0.98, 7.45 Hz, 2H), 7.06 (dd, J = 0.98, 8.30 Hz, 2H), 3.93 (s, 6H) 
13
C NMR (126 MHz, CDCl3)  157.5, 149.0, 145.6, 131.3, 131.0, 126.1, 121.5, 111.6, 55.8 
LR-MS (CI): 293.1 (M+H)
+
 
N-(2-methoxybenzoyl)-2-amino-2’-methoxyacetophenone (21) 
Amino ketone hydrochloride 19 (350 mg, 1.73 mmol) was combined with 5 mL of CH2Cl2. 2-
methoxybenzoyl chloride (281 mg, 1.65 mmol, 0.95 eq.) was added. The reaction was cooled in 
an ice-bath before the addition of triethylamine (337 mg, 3.3 mmol, 1.9 eq.). The reaction stirred 
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at room temperature overnight. The solution was concentrated and the residue purified by 
column chromatography (2:1 CH2Cl2:EtOAc) to yield 415 mg (84%) of product as a white solid.  
1
H NMR (499 MHz, CDCl3)  9.11 (br. s., 1H), 8.25 (dd, J = 1.71, 7.81 Hz, 1H), 8.00 (dd, J = 
1.83, 7.69 Hz, 1H), 7.56 (ddd, J = 1.95, 7.08, 8.55 Hz, 1H), 7.48 (ddd, J = 1.83, 7.26, 8.24 Hz, 
1H), 7.00 - 7.13 (m, 4H), 4.98 (d, J = 4.39 Hz, 2H), 4.10 (s, 3H), 4.00 (s, 3H) 
13
C NMR (126 MHz, CDCl3)  195.5, 165.3, 160.0, 158.2, 135.1, 133.0, 132.4, 131.2, 125.0, 
121.6, 121.3, 121.0, 112.0, 111.6, 56.3, 55.9, 52.2 
2,5-bis(2-methoxyphenyl)oxazole (22) 
Keto amide 22 (150 mg, 0.5 mmol) was dissolved in 2 mL pyridine. POCl3 (0.25 mL) was 
slowly added to the reaction mixture, which turned bright yellow. The solution stirred at room 
temperature for 4 hours. The reaction mixture was diluted with 50 mL EtOAc and washed with 
10 mL sat. NaHCO3, 10 mL 0.5N HCl, and 10 mL brine. The organic layer was dried over 
Na2SO4 and concentrated. The crude residue was purified by column chromatography (1:1 
EtOAc:hexanes) to yield 114 mg (81%) of the diaryloxazole. 
1
H NMR (500 MHz, CDCl3)  8.06 (dd, J = 1.72, 7.72 Hz, 1H), 7.89 (dd, J = 1.72, 7.72 Hz, 1H), 
7.70 (s, 1H), 7.39 - 7.47 (m, 1H), 7.30 (ddd, J = 1.72, 7.40, 8.25 Hz, 1H), 7.03 - 7.12 (m, 3H), 
6.99 (d, J = 8.36 Hz, 1H), 4.01 (s, 3H), 3.97 - 3.99 (m, 3H) 
13
C NMR (126 MHz, CDCl3)  170.4, 158.6, 157.8, 155.9, 153.3, 131.7, 130.3, 129.1, 127.8, 
126.2, 121.0, 120.8, 112.2, 111.1, 56.3, 55.7 
2,5-bis(2-methoxyphenyl)thiazole (22b) 
Ketoamide (100 mg, 0.33 mmol) and Lawesson’s reagent (202 mg, 0.5 mmol) were refluxed in 5 
mL THF for 6 hours. After cooling to room temperature the THF was removed by rotary 
evaporation. The residue was dissolved in CH2Cl2, washed with brine, dried over MgSO4 and 
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concentrated. The crude product was purified by column chromatography (2:1  1:1 
hexanes:EtOAc), yielding 32.7 mg (33%) of the product as a light yellow foam. 
1
H NMR (500 MHz, CDCl3)  8.42 (dd, J = 1.72, 7.72 Hz, 1H), 8.30 (s, 1H), 7.68 (dd, J = 1.61, 
7.61 Hz, 1H), 7.35 - 7.44 (m, 1H), 7.27 - 7.33 (m, 1H), 7.07 - 7.14 (m, 1H), 6.96 - 7.06 (m, 3H), 
4.04 (s, 3H), 3.95 (s, 3H) 
13
C NMR (126 MHz, CDCl3)  162.0, 156.5, 155.9, 140.3, 135.2, 130.6, 129.2, 129.0, 128.3, 
122.9, 121.3, 121.3, 111.7, 111.6, 55.8, 55.8 
General procedure B 
N-Boc-protect amino acid (1.0 eq) and N,O-dimethylhydroxylamine hydrochloride (2.0 eq) were 
combined with isopropyldiethylamine (3.0 eq) in DMF (0.33 M) and stirred for 5 minutes until 
solution is homogeneous. HOBt (1.2 eq) and EDC hydrochloride (1.2 eq) were added, and the 
solution stirred for two hours. The reaction mixture was diluted with cold water and extracted 
several times with ethyl acetate. The combined organic layers were washed with 0.5 M cold HCl, 
several times with brine, and dried over MgSO4. The solvent was removed by rotary evaporation, 
leaving a thick oil, which was used without further purification. 
N-Boc-Ala Weinreb amide (23a) 
Following general procedure B, the product was isolated as a tan solid in 99% 
1
H NMR (499 MHz, CDCl3)  5.17 - 5.32 (m, 1H), 4.56 - 4.77 (m, 1H), 3.77 (s, 3H), 3.21 (s, 
3H), 1.44 (s, 9H), 1.31 (d, J = 6.84 Hz, 3H) 
N-Boc-Val Weinreb amide (23b) 
Following general procedure B, the product was isolated as a thick syrup in 99% yield 
1
H NMR (499 MHz, CDCl3)  5.05 - 5.23 (m, 1H), 4.49 - 4.64 (m, 1H), 3.78 (s, 3H), 3.22 (s, 
3H), 1.93 - 2.04 (m, 1H), 1.44 (s, 9H), 0.96 (d, J = 6.84 Hz, 3H), 0.91 (d, J = 6.84 Hz, 3H) 
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N-Boc-Leu Weinreb amide (23c) 
Following general procedure B, the product was isolated as a thick syrup in 99% yield 
1
H NMR (499 MHz, CDCl3)  4.99 - 5.16 (m, 1H), 4.51 - 4.86 (m, 1H), 3.79 (s, 3H), 3.19 (s, 
3H), 1.61 - 1.82 (m, 1H), 1.36 - 1.51 (m, 12H), 0.96 (d, J = 6.59 Hz, 3H), 0.92 (d, J = 6.59 Hz, 
3H) 
N-Boc-2-amino-1-phenylpropanone (24) 
100 mg (0.43 mmol) of N-Boc-Ala Weinreb amide was dissolved in THF and cooled to -78°C. 
iPrMgCl (0.2 mL of a 2.0M solution in THF, 0.40 mmol, 0.95 eq.) was added dropwise. After 
stirring for 30 minutes, phenylmagnesium chloride (0.27 mL of a 2.0M solution in THF, 0.54 
mmol, 1.25 eq) was added. The reaction was allowed to warm to room temperature and stirred 
overnight. The reaction was quenched with cold 0.5N HCl and extracted several times with ethyl 
acetate. The combined organic extracts were washed with brine, dried over Na2SO4 and 
concentrated by rotary evaporation. The crude residue was purified by 7:2 hexanes:EtOAc to 
yield 59.7 mg (56%) of a clear oil. 
1
H NMR (400 MHz, CDCl3)  7.96 (d, J = 7.57 Hz, 2H), 7.54 - 7.61 (m, 1H), 7.44 - 7.51 (m, 
2H), 5.48 - 5.67 (m, 1H), 5.29 (d, J = 7.32 Hz, 1H), 1.38 (d, J = 7.08 Hz, 3H) 
13
C NMR (101 MHz, CDCl3)  199.7, 155.4, 134.4, 133.9, 129.0, 128.9, 79.9, 51.3, 28.6, 20.1 
General procedure C 
2-iodophenol, alkyl bromide, and potassium carbonate were heated to 95°C in DMF for 24 
hours. After cooling to room temperature, the reaction mixture was neutralized slowly with 6M 
HCl and diluted with brine. The reaction mixture was extracted with ethyl acetate, dried over 
Na2SO4, and concentrated by rotary evaporation. The crude product was purified by column 
chromatography (6:1 hexanes : EtOAc) to yield the product. 
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1-iodo-2-isobutoxybenzene (27a) 
Following general procedure C, the product was obtained as a clear oil in 64% yield. 
1
H NMR (499 MHz, CDCl3)  7.78 (dd, J = 1.59, 7.69 Hz, 1H), 7.20 - 7.38 (m, 1H), 6.79 (dd, J 
= 1.34, 8.18 Hz, 1H), 6.70 (dt, J = 1.46, 7.57 Hz, 1H), 3.79 (d, J = 6.35 Hz, 2H), 2.17 (spt, J = 
6.60 Hz, 1H), 1.10 (d, J = 6.84 Hz, 6H) 
13
C NMR (126 MHz, CDCl3)  157.8, 139.6, 129.6, 122.4, 112.1, 86.9, 75.9, 29.2, 20.5 
1-iodo-2-isopropoxybenzene (27b) 
Following general procedure C, the product was obtained as a clear oil in 62% yield. 
1
H NMR (500 MHz, CDCl3)  7.78 (dd, J = 1.61, 7.83 Hz, 1H), 7.24 - 7.30 (m, 1H), 6.84 (dd, J 
= 1.18, 8.04 Hz, 1H), 6.66 - 6.73 (m, 1H), 4.57 (spt, J = 6.07 Hz, 1H), 1.40 (d, J = 6.00 Hz, 6H) 
N-Boc-2-amino-1-(2-isobutoxyphenyl)propanone (25) 
In a flame-dried three-neck flask fitted with a condenser and septa magnesium turnings (106 mg, 
4.4 mmol, 2.2 eq.) were combined with 2 mL dry THF. 1-iodo-2-isobutoxybenzene was added to 
the reaction mixture, followed by two crystals of iodine. The reaction mixture was heated to 
reflux until no more magnesium was being consumed. The reaction was cooled to room 
temperature. The procedure described for 24 was followed, with the Grignard reagent being 
added via cannulation. The crude residue was purified by silica gel chromatography (6:1 
hexanes:EtOAc) to yield 164 mg (25%) of a clear oil. 
1
H NMR (500 MHz, CDCl3)  7.73 (d, J = 7.50 Hz, 1H), 7.46 (t, J = 7.93 Hz, 1H), 6.99 (t, J = 
7.50 Hz, 1H), 6.94 (d, J = 8.36 Hz, 1H), 5.51 - 5.64 (m, 1H), 5.28 - 5.40 (m, 1H), 3.84 - 3.92 (m, 
J = 6.65 Hz, 1H), 3.76 - 3.83 (m, 1H), 2.10 - 2.29 (m, 1H), 1.44 (s, 9H), 1.33 (d, J = 7.07 Hz, 
3H), 1.08 (d, J = 6.86 Hz, 6H) 
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13
C NMR (126 MHz, CDCl3)  201.5, 158.3, 155.4, 134.3, 131.3, 120.8, 112.5, 79.4, 75.6, 55.5, 
28.6, 28.4, 19.7, 19.7, 19.2 
General procedure D 
Ortho-alkoxyiodide (1.25 eq.) and Weinreb amide were dissolved in dry THF. The reaction was 
cooled to -78°C and stirred for 15 minutes. Isopropylmagnesium chloride (2.0M in THF) was 
added dropwise. After completion of addition, the dry ice bath was removed, and the reaction 
mixture was allowed to warm to room temperature overnight. The reaction was diluted with 
ethyl acetate and carefully quenched with 0.5M ice-cold HCl. The organic layer was washed 
further with 0.5M HCl, brine, and dried over Na2SO4. The crude product was obtained by rotary 
evaporation. Column chromatography (hexanes/ethyl acetate) yielded the product as a clear oil. 
N-Boc-2-amino-1-(2-methoxyphenyl)propanone (26a) 
Following general procedure D, the product was isolated in 53% yield. 
1
H NMR (500 MHz, CDCl3)  7.76 (d, J = 6.65 Hz, 1H), 7.44 - 7.54 (m, 1H), 6.99 - 7.06 (m, 
1H), 6.97 (d, J = 8.36 Hz, 1H), 5.53 - 5.64 (m, 1H), 5.32 (d, J = 7.50 Hz, 1H), 3.92 (s, 3H), 1.44 
(s, 9H), 1.31 (d, J = 7.07 Hz, 3H) 
13
C NMR (126 MHz, CDCl3)  201.1, 158.8, 155.5, 134.5, 131.5, 125.3, 121.1, 111.8, 79.5, 55.8, 
55.5, 28.6, 19.0 
N-Boc-2-amino-1-(2-isobutoxy)-3-methylbutanone (26b) 
Following the general procedure D, the product was isolated in 27% yield. 
1
H NMR (400 MHz, CDCl3)  7.65 (dd, J = 1.83, 7.69 Hz, 1H), 7.38 - 7.50 (m, 1H), 6.88 - 7.03 
(m, 2H), 5.43 (br. s., 2H), 3.91 (dd, J = 6.10, 8.79 Hz, 1H), 3.73 (dd, J = 7.32, 8.79 Hz, 1H), 2.05 
- 2.31 (m, 2H), 1.45 (s, 9H), 1.03 - 1.10 (m, 6H), 1.00 (d, J = 6.84 Hz, 3H), 0.65 (d, J = 6.84 Hz, 
3H) 
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N-Boc-2-amino-1-(2-isopropoxyphenyl)-4-methylpentanone (26c) 
Following general procedure D, the product was isolated in 62% yield. 
1
H NMR (499 MHz, CDCl3)  7.62 (dd, J = 1.59, 7.69 Hz, 1H), 7.38 - 7.48 (m, 1H), 6.88 - 7.01 
(m, 2H), 5.37 - 5.50 (m, 1H), 5.33 (br. s., 1H), 4.63 - 4.77 (m, 1H), 1.74 (br. s., 1H), 1.58 (br. s., 
1H), 1.47 (d, J = 6.10 Hz, 3H), 1.43 (s, 9H), 1.39 (d, J = 6.10 Hz, 3H), 1.29 - 1.37 (m, 2H), 0.98 
(d, J = 6.35 Hz, 3H), 0.85 (d, J = 6.59 Hz, 3H) 
N-Boc-2-amino-1-(2-isobutoxyphenyl)-4-methylpentanone (26d) 
Following general procedure D, the product was isolated in 64% yield. 
1
H NMR (499 MHz, CDCl3)  7.61 (dd, J = 1.46, 7.57 Hz, 1H), 7.41 - 7.47 (m, 1H), 6.99 (t, J = 
7.45 Hz, 1H), 6.95 (d, J = 8.06 Hz, 1H), 5.25 - 5.43 (m, 2H), 3.91 (dd, J = 6.10, 8.79 Hz, 1H), 
3.70 - 3.80 (m, 1H), 2.12 - 2.30 (m, 1H), 1.67 - 1.81 (m, 1H), 1.55 - 1.61 (m, 1H), 1.43 (s, 9H), 
1.01 - 1.08 (m, 7H), 0.94 (d, J = 6.35 Hz, 3H), 0.84 (d, J = 6.59 Hz, 3H) 
General procedure E 
Crude amidoketone was dissolved in a solution of HCl (4M) in ether, and stirred at room 
temperature for up to 2 hours. The product was isolated as the hydrochloride salt by rotary 
evaporation of the solvent in nearly quantitative yield. 
2-amino-1-(2-isobutoxyphenyl)-3-methylbutanone hydrochloride (28a) 
Following general procedure E, the product was obtained in 100% yield. 
1
H NMR (499 MHz, CD3OD)  7.76 (dd, J = 1.59, 7.93 Hz, 1H), 7.56 - 7.66 (m, 1H), 7.20 (d, J 
= 8.30 Hz, 1H), 7.10 (dt, J = 0.85, 7.51 Hz, 1H), 5.10 (d, J = 3.17 Hz, 1H), 4.05 (dd, J = 5.98, 
9.16 Hz, 1H), 3.90 (dd, J = 7.08, 9.28 Hz, 1H), 2.39 (d, J = 3.42 Hz, 1H), 2.11 - 2.25 (m, 1H), 
1.06 - 1.20 (m, 9H), 0.83 (d, J = 7.08 Hz, 3H) 
2-amino-1-(2-isobutoxyphenyl)-4-methylpentanone hydrochloride (28b) 
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Following general procedure E, the product was obtained in 93% yield. 
1
H NMR (499 MHz, CD3OD)  7.70 (dd, J = 1.95, 7.81 Hz, 1H), 7.59 - 7.65 (m, 1H), 7.20 (d, J 
= 7.81 Hz, 1H), 7.09 (dt, J = 0.85, 7.51 Hz, 1H), 5.13 (dd, J = 4.88, 8.79 Hz, 1H), 4.92 (s, 3H), 
4.03 (dd, J = 6.10, 9.52 Hz, 1H), 3.91 (dd, J = 7.32, 9.28 Hz, 1H), 2.11 - 2.26 (m, 1H), 1.69 - 
1.81 (m, 1H), 1.61 - 1.68 (m, 2H), 1.06 - 1.12 (m, 6H), 0.99 (d, J = 6.59 Hz, 3H), 0.90 (d, J = 
6.59 Hz, 3H) 
Methyl isobutylsalicylate (31) 
Methyl salicylate (1.52 g, 10 mmol), isobutyl bromide (2.74 g, 20 mmol) and potassium 
carbonate (2.76 g, 20 mmol) were heated to 75°C in 20 mL for 20 hours. Upon cooling to room 
temperature the reaction mixture was slowly neutralized with 1N HCl. 100 mL brine was added, 
and the aqueous layer was extracted with ethyl acetate (3 x 50 mL). The combined organic 
extracts were washed with brine, dried over Na2SO4, and concentrated to yield the product as a 
light yellow oil in 99% yield. 
1
H NMR (400 MHz, CDCl3)  7.74 - 7.81 (m, 1H), 7.43 (ddd, J = 1.83, 7.45, 8.30 Hz, 1H), 6.91 
- 6.98 (m, 2H), 3.89 (s, 3H), 3.79 (d, J = 6.35 Hz, 2H), 2.14 (spt, J = 6.30 Hz, 1H), 1.05 (d, J = 
6.84 Hz, 6H) 
2-isobutoxybenzoic acid (32) 
Methyl 2-isobutoxysalicylic acid (1.90 g, 9.1 mmol) was dissolved in 10 mL MeOH. 10 mL 2N 
NaOH was added, and the reaction mixture stirred at room temperature for 2 hours. The 
methanol was removed by rotary evaporation, and the residue carefully neutralized with 1N HCl. 
The aqueous layer was extracted several times with EtOAc; the combined organic extracts were 
washed with brine, dried over Na2SO4, and concentrated by rotary evaporation to yield 1.631 g 
(91%) of a clear oil which solidified upon standing. 
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1
H NMR (400 MHz, CDCl3)  8.16 (dd, J = 1.95, 7.81 Hz, 1H), 7.51 - 7.57 (m, 1H), 7.07 - 7.14 
(m, 1H), 7.01 - 7.05 (m, 1H), 4.01 (d, J = 6.59 Hz, 2H), 2.22 (td, J = 6.62, 13.37 Hz, 1H), 1.05 - 
1.11 (m, 6H) 
N-(2-isobutoxybenzoyl)-2-amino-4-methyl-1-(2-isobutoxyphenyl)-1-pentanone (29) 
N-acyl aminoketone (66 mg, 0.22 mmol) and 2-isobutoxybenzoic acid (43 mg, 0.22 mmol, 1 eq.) 
dissolved in 0.66 mL DMF. Diisopropylethylamine (57 mg, 0.44 mmol, 2 eq) was added and the 
reaction mixture stirred at room temperature for 5 minutes. EDC hydrochloride (46 mg, 0.242 
mmol, 1.1 eq.) and HOBt (33 mg, 0.242 mmol, 1.1 eq.) were added, and the reaction mixture 
stirred for 3 hours. The reaction mixture was diluted with brine and washed exhaustively with 
dichloromethane. The combined organic extracts were washed with 1N HCl, brine, dried over 
Na2SO4, and concentrated by rotary evaporation to yield 90.1 mg (68%) of an off-white foam.  
1
H NMR (499 MHz, CDCl3)  8.83 (d, J = 8.06 Hz, 1H), 7.74 - 7.83 (m, 1H), 7.63 - 7.72 (m, 
1H), 7.39 - 7.50 (m, 2H), 7.31 - 7.38 (m, 1H), 6.93 - 7.07 (m, 4H), 3.85 - 4.01 (m, 3H), 3.74 - 
3.84 (m, 1H), 2.39 (td, J = 6.59, 13.18 Hz, 1H), 2.24 (td, J = 6.62, 13.37 Hz, 1H), 1.65 - 1.86 (m, 
2H), 1.45 - 1.60 (m, 1H), 1.13 (dd, J = 6.84, 7.81 Hz, 6H), 1.04 - 1.10 (m, 6H), 0.93 - 0.98 (m, 
3H), 0.82 (d, J = 6.35 Hz, 3H) 
4-isobutyl-2,5-bis(2-isobutoxyphenyl)oxazole (30) 
N-acylaminoketone (97 mg) was dissolved in 1.5 mL pyridine. 0.5 mL POCl3 was added 
dropwise; the reaction stirred at room temperature for 6 hours. The reaction was quenched 
slowly with ice-cold water. 25 mL EtOAc and 5 mL 1N HCl were added. The organic layer was 
washed with 15 mL brine, dried over Na2SO4, and concentrated by rotary evaporation. The crude 
residue was purified by preparative TLC (3:1 hexanes/EtOAc) to yield 16.5 mg (20%) of a white 
solid. 
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1
H NMR (400 MHz, CDCl3)  7.98 (d, J = 6.84 Hz, 1H), 7.43 (dd, J = 1.71, 7.57 Hz, 1H), 7.29 - 
7.38 (m, 2H), 6.89 - 7.07 (m, 4H), 3.83 (d, J = 6.59 Hz, 2H), 3.74 (d, J = 6.59 Hz, 2H), 2.52 (d, J 
= 7.32 Hz, 2H), 1.90 - 2.25 (m, 3H), 0.99 - 1.06 (m, 6H), 0.92 (d, J = 6.84 Hz, 6H), 0.87 (d, J = 
6.59 Hz, 6H)    
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